<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions to prevent and treat corticosteroid‐induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy - Bell, JM - 2017 | Cochrane Library</title> <meta content="Interventions to prevent and treat corticosteroid‐induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy - Bell, JM - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010899.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions to prevent and treat corticosteroid‐induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy - Bell, JM - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010899.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010899.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions to prevent and treat corticosteroid‐induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy" name="citation_title"/> <meta content="Jennifer M Bell" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Michael D Shields" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="m.shields@qub.ac.uk" name="citation_author_email"/> <meta content="Janet Watters" name="citation_author"/> <meta content="Belfast Health and Social Care Trust" name="citation_author_institution"/> <meta content="Alistair Hamilton" name="citation_author"/> <meta content="Belfast Health and Social Care Trust" name="citation_author_institution"/> <meta content="Timothy Beringer" name="citation_author"/> <meta content="Belfast Health and Social Care Trust" name="citation_author_institution"/> <meta content="Mark Elliott" name="citation_author"/> <meta content="Musgrave Park Hospital, Belfast Health and Social Care Trust" name="citation_author_institution"/> <meta content="Rosaline Quinlivan" name="citation_author"/> <meta content="UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery and Great Ormond Street" name="citation_author_institution"/> <meta content="Sandya Tirupathi" name="citation_author"/> <meta content="Royal Belfast Hospital for Sick Children" name="citation_author_institution"/> <meta content="Bronagh Blackwood" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD010899.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/01/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010899.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010899.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010899.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Weight‐Bearing; Adrenal Cortex Hormones [adverse effects]; Bone Density [drug effects]; Bone Density Conservation Agents [*therapeutic use]; Calcium [therapeutic use]; Diphosphonates [therapeutic use]; Imidazoles [therapeutic use]; Muscular Dystrophy, Duchenne [*drug therapy]; Osteoporosis [chemically induced, complications, *drug therapy, prevention &amp; control]; Osteoporotic Fractures [etiology, *prevention &amp; control]; Randomized Controlled Trials as Topic; Risedronic Acid [therapeutic use]; Spinal Fractures [etiology, *prevention &amp; control]; Vibration [*therapeutic use]; Vitamin D [therapeutic use]; Zoledronic Acid" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010899.pub2&amp;doi=10.1002/14651858.CD010899.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="7LavyS58";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010899\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010899\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010899.pub2",title:"Interventions to prevent and treat corticosteroid\\u2010induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy",firstPublishedDate:"Jan 24, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010899.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010899.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010899.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010899.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010899.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010899.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010899.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010899.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010899.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010899.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5222 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010899.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-sec-0081"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-sec-0040"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-sec-0041"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/appendices#CD010899-sec-0085"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions to prevent and treat corticosteroid‐induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#CD010899-cr-0002">Jennifer M Bell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#CD010899-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Michael D Shields</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#CD010899-cr-0004">Janet Watters</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#CD010899-cr-0005">Alistair Hamilton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#CD010899-cr-0006">Timothy Beringer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#CD010899-cr-0007">Mark Elliott</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#CD010899-cr-0008">Rosaline Quinlivan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#CD010899-cr-0009">Sandya Tirupathi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information#CD010899-cr-0010">Bronagh Blackwood</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information/en#CD010899-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 January 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010899.pub2">https://doi.org/10.1002/14651858.CD010899.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010899-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010899-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010899-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010899-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010899-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010899-abs-0001" lang="en"> <section id="CD010899-sec-0001"> <h3 class="title" id="CD010899-sec-0001">Background</h3> <p>Corticosteroid treatment is considered the 'gold standard' for Duchenne muscular dystrophy (DMD); however, it is also known to induce osteoporosis and thus increase the risk of vertebral fragility fractures. Good practice in the care of those with DMD requires prevention of these adverse effects. Treatments to increase bone mineral density include bisphosphonates and vitamin D and calcium supplements, and in adolescents with pubertal delay, testosterone. Bone health management is an important part of lifelong care for patients with DMD. </p> </section> <section id="CD010899-sec-0002"> <h3 class="title" id="CD010899-sec-0002">Objectives</h3> <p>To assess the effects of interventions to prevent or treat osteoporosis in children and adults with DMD taking long‐term corticosteroids; to assess the effects of these interventions on the frequency of vertebral fragility fractures and long‐bone fractures, and on quality of life; and to assess adverse events. </p> </section> <section id="CD010899-sec-0003"> <h3 class="title" id="CD010899-sec-0003">Search methods</h3> <p>On 12 September 2016, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL Plus to identify potentially eligible trials. We also searched the Web of Science ISI Proceedings (2001 to September 2016) and three clinical trials registries to identify unpublished studies and ongoing trials. We contacted correspondence authors of the included studies in the review to obtain information on unpublished studies or work in progress. </p> </section> <section id="CD010899-sec-0004"> <h3 class="title" id="CD010899-sec-0004">Selection criteria</h3> <p>We considered for inclusion in the review randomised controlled trials (RCTs) and quasi‐RCTs involving any bone health intervention for corticosteroid‐induced osteoporosis and fragility fractures in children, adolescents, and adults with a confirmed diagnosis of DMD. The interventions might have included oral and intravenous bisphosphonates, vitamin D supplements, calcium supplements, dietary calcium, testosterone, and weight‐bearing activity. </p> </section> <section id="CD010899-sec-0005"> <h3 class="title" id="CD010899-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed reports and selected potential studies for inclusion, following standard Cochrane methodology. We contacted study authors to obtain further information for clarification on published work, unpublished studies, and work in progress. </p> </section> <section id="CD010899-sec-0006"> <h3 class="title" id="CD010899-sec-0006">Main results</h3> <p>We identified 18 potential studies, of which two, currently reported only as abstracts, met the inclusion criteria for this review. Too little information was available for us to present full results or adequately assess risk of bias. The participants were children aged five to 15 years with DMD, ambulant and non‐ambulant. The interventions were risedronate versus no treatment in one trial (13 participants) and whole‐body vibration versus a placebo device in the second (21 participants). Both studies reported improved bone mineral density with the active treatments, with no improvement in the control groups, but the abstracts did not compare treatment and control conditions. All children tolerated whole‐body vibration treatment. No study provided information on adverse events. Two studies are ongoing: one investigating whole‐body vibration, the other investigating zoledronic acid. </p> </section> <section id="CD010899-sec-0007"> <h3 class="title" id="CD010899-sec-0007">Authors' conclusions</h3> <p>We know of no high‐quality evidence from RCTs to guide use of treatments to prevent or treat corticosteroid‐induced osteoporosis and reduce the risk of fragility fractures in children and adults with DMD; only limited results from two trials reported in abstracts were available. We await formal trial reports. Findings from two ongoing relevant studies and two trials, for which only abstracts are available, will be important in future updates of this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010899-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010899-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010899-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010899-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010899-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010899-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010899-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010899-abs-0003" lang="en"> <h3>Treatments to prevent and treat thinning of bones and prevent fractures caused by corticosteroids in Duchenne muscular dystrophy </h3> <p><b>Review question</b> </p> <p>What are the effects of treatments to prevent or treat thinning of bones (osteoporosis) and prevent fragile bones from breaking (fragility fractures) in adults and children with Duchenne muscular dystrophy (DMD) who are taking long‐term corticosteroids? </p> <p><b>Background</b> </p> <p>DMD is an inherited condition, affecting about one in 3500 to one in 6000 newborn boys. DMD causes muscle weakness that becomes more severe with age. Muscle weakness is widespread, affecting movement, the digestive system, breathing, and the heart. The pattern of weakness mainly affects muscles near the trunk, around the shoulders, and at the hips. If untreated, DMD leads to death in the late teens from breathing or heart complications. A child with DMD often shows the first signs of this disease before starting school. If untreated, he will lose the ability to walk by the age of 13 years and need to use a wheelchair. There is no cure for DMD, but medicines called corticosteroids slow muscle damage and enable boys with DMD to walk for longer. Boys with DMD also tend to have weak bones because of their weak muscles and reduced mobility. </p> <p>Corticosteroids cause osteoporosis (thinning of the bones), which makes the bones more fragile and liable to fracture (break). Therapies, such as vitamin D and calcium supplements, more calcium in the diet, medicines called bisphosphonates, testosterone, and weight‐bearing exercise, might be able to strengthen bone to prevent and treat osteoporosis and prevent fractures in people with DMD who are taking corticosteroids. Investigators use bone density as a measure of how strong the bone is and to measure the effects of therapies to prevent and treat osteoporosis. </p> <p><b>Study characteristics</b> </p> <p>We searched the medical literature comprehensively, finding two completed trials. Only brief reports (abstracts) of these trials are available. The participants were children aged from five to 15 years with DMD who were able to walk and not able to walk. The treatments were risedronate versus no treatment in one trial (with 13 participants) and whole‐body vibration versus a placebo (inactive) device in the other (with 21 participants). </p> <p><b>Key results and quality of the evidence</b> </p> <p>We found two completed studies that were potentially eligible for this review, for which full results have not yet been published, and two studies ongoing at the time of the search. These studies are looking at the effects of whole‐body vibration (two studies), risedronate, and zoledronic acid. Both completed trials, presented as abstracts only, reported an improvement in bone mineral density in children who received active treatment and no improvement in children in the control (placebo or no treatment) groups. However, the reports did not report results for the comparison of treatment versus control groups, which means that it is not possible to draw conclusions about the effectiveness of either treatment. All children tolerated whole‐body vibration treatment. Neither study provided information on adverse events. </p> <p>We know of no evidence from randomised clinical trials to guide use of treatments to prevent or treat osteoporosis and prevent fragility fractures in people with DMD taking corticosteroids. </p> <p>Searches are current to September 2016.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010899-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010899-sec-0081"></div> <h3 class="title" id="CD010899-sec-0082">Implications for practice</h3> <section id="CD010899-sec-0082"> <p>We know of no evidence from high‐quality randomised controlled trials (RCTs) about the efficacy of interventions to prevent or treat corticosteroid‐induced osteoporosis and prevent osteoporotic fragility fractures in DMD in children and adults, other than limited results from two trials reported in abstracts. There is no evidence of harm, but formal trial reports are awaited. Findings from two ongoing relevant studies and the two trials for which only abstracts are available will be important in future updates of this review. </p> </section> <h3 class="title" id="CD010899-sec-0083">Implications for research</h3> <section id="CD010899-sec-0083"> <p>There is a need for good‐quality RCTs of treatments for bone protection and treatment of corticosteroid‐induced osteoporosis in Duchenne muscular dystrophy (DMD). </p> <p>When fully published, the included and ongoing studies of bisphosphonates and weight‐bearing activity will be important contributors to this review. Nevertheless, future RCT design and delivery needs to ensure the following: </p> <p> <ul id="CD010899-list-0009"> <li> <p>employment of an adequate sample size;</p> </li> <li> <p>that the clinical indications for starting interventions are addressed;</p> </li> <li> <p>that dose, duration, and type of intervention (treatment strategies) are addressed;</p> </li> <li> <p>employment of outcomes in addition to bone density Z‐scores relevant to children or adolescents, including the number of vertebral fractures, with a clear definition of type of fracture. Pain and quality of life should be also assessed during the trial period and measured using validated scales; and </p> </li> <li> <p>assessment of children, adolescents, and adults with DMD or those who are ambulant and non‐ambulant separately, as appropriate. </p> </li> </ul> </p> <p>In this group of patients it may not be ethical to withhold treatment or give a placebo, so comparisons could be made to routine care, alternative interventions, or between different treatment groups. It is important that the RCTs consider that age, weight, duration of corticosteroid therapy, mobility, weight‐bearing activity, delayed puberty, and growth therapy will affect the outcome measures. Patient groups (children, adolescents, and adults) could be either assessed in separately designed trials, or results could be analysed separately per group to reflect these factors. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010899-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010899-sec-0022"></div> <section id="CD010899-sec-0023"> <h3 class="title" id="CD010899-sec-0023">Description of the condition</h3> <section id="CD010899-sec-0024"> <h4 class="title">Duchenne muscular dystrophy (DMD)</h4> <p>Duchenne muscular dystrophy (DMD) is a progressive disorder affecting skeletal, cardiac, and smooth muscle (<a href="./references#CD010899-bbs2-0085" title="EmeryAE . The muscular dystrophies. BMJ1998;317(7164):991‐5. [PUBMED: 9765171] ">Emery 1998</a>; <a href="./references#CD010899-bbs2-0229" title="VoisinV , de laPorteS . Therapeutic strategies for Duchenne and Becker dystrophies. International Review of Cytology2004;240:1‐30. [PUBMED: 15548414] ">Voisin 2004</a>). Inheritance is sex‐linked recessive, and the condition has an incidence of one in 3500 to one in 6000 male live births (<a href="./references#CD010899-bbs2-0084" title="EmeryAE . Population frequencies of inherited neuromuscular diseases ‐ a world survey. Neuromuscular Disorders1991;1(1):19‐29. [PUBMED: 1822774] ">Emery 1991</a>; <a href="./references#CD010899-bbs2-0086" title="EmeryFM , MuntoniF . Duchenne muscular dystrophy. 3rd Edition. New York: Oxford University Press, 2003. ">Emery 2003</a>; <a href="./references#CD010899-bbs2-0094" title="FlaniganKM . The muscular dystrophies. Seminars in Neurology2012;32(3):255‐63. [PUBMED: 23117950] ">Flanigan 2012</a>). DMD is caused by deletions, duplications or mutations in the dystrophin gene located at Xp21, resulting in the absence or low levels of the protein known as dystrophin (<a href="./references#CD010899-bbs2-0062" title="ChaturvediLS , MukherjeeM , SrivastavaS , MittalRD , MittalB . Point mutation and polymorphism in Duchenne/Becker muscular dystrophy (D/BMD) patients. Experimental &amp; Molecular Medicine2001;33(4):251‐6. [PUBMED: 11795488] ">Chaturvedi 2001</a>; <a href="./references#CD010899-bbs2-0093" title="FlaniganKM , DunnDM , vonNiederhausernA , SoltanzadehP , GappmaierE , HowardMT , et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Human Mutation2009;30(12):1657‐66. [PUBMED: 19937601] ">Flanigan 2009</a>; <a href="./references#CD010899-bbs2-0142" title="LeeBL , NamSH , LeeJH , KiCS , LeeM , LeeJ . Genetic analysis of dystrophin gene for affected male and female carriers with Duchenne/Becker muscular dystrophy in Korea. Journal of Korean Medical Science2012;27(3):274‐80. [PUBMED: 22379338] ">Lee 2012</a>; <a href="./references#CD010899-bbs2-0166" title="MuntoniF , TorelliS , FerliniA . Dystrophin and mutations: one gene, several proteins, multiple phenotypes. The Lancet Neurology2003;2(12):731‐40. [PUBMED: 14636778] ">Muntoni 2003</a>; <a href="./references#CD010899-bbs2-0212" title="SoltanzadehP , FriezMJ , DunnD , vonNiederhausernA , GurvichOL , SwobodaKJ , et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscular Disorders2010;20(8):499‐504. [PUBMED: 20630757] ">Soltanzadeh 2010</a>). Dystrophin is a large protein located on the sarcolemmal membrane. It forms part of the dystrophin‐associated protein complex and is involved in membrane integrity. Absence of dystrophin leads to membrane damage and progressive dystrophic changes within the muscle (<a href="./references#CD010899-bbs2-0050" title="BlakeDJ , WeirA , NeweySE , DaviesKE . Function and genetics of dystrophin and dystrophin‐related proteins in muscle. Physiological Reviews2002;82(2):291‐329. [PUBMED: 11917091] ">Blake 2002</a>; <a href="./references#CD010899-bbs2-0071" title="DeconinckN , DanB . Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatric Neurology2007;36(1):1‐7. [PUBMED: 17162189] ">Deconinck 2007</a>). Affected boys appear normal at birth and first show signs of muscle weakness in early childhood, often as a toddler. Without treatment, they become wheelchair dependent by 13 years of age. Without respiratory support, death occurs in the late teens or early twenties. Because of postural imbalance and reduced muscular support to the spine, scoliosis (spinal deformity) typically develops. Scoliosis of the thoracic region restricts movement of the ribs making breathing even more difficult for already weakened respiratory muscles. However, in recent years, prognosis has improved substantially with the introduction of non‐invasive ventilation support along with cough‐assist technology and co‐ordinated multidisciplinary care (<a href="./references#CD010899-bbs2-0059" title="BushbyK , FinkelR , BirnkrantD J , CaseLE , ClemensPR , CripeL , et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology2010;9(2):177‐89. [PUBMED: 19945914] ">Bushby 2010</a>; <a href="./references#CD010899-bbs2-0172" title="PassamanoL , TagliaA , PalladinoA , ViggianoE , D'AmbrosioP , ScutiferoM , et al. Improvement of survival in Duchenne Muscular dystrophy: retrospective analysis of 835 patients. Acta Myologica2012;31(2):121‐5. [PUBMED: 23097603] ">Passamano 2012</a>). </p> <p>Corticosteroid treatment is now considered the 'gold standard' for DMD, and corticosteroid‐induced osteoporosis is an important emerging problem (<a href="./references#CD010899-bbs2-0059" title="BushbyK , FinkelR , BirnkrantD J , CaseLE , ClemensPR , CripeL , et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology2010;9(2):177‐89. [PUBMED: 19945914] ">Bushby 2010</a>). Corticosteroids have been shown to slow the decline in muscle function and may protect cardiac and respiratory function. Corticosteroid‐treated boys lose the ability to walk at around 12 to 14 years of age, compared with seven to 13 years for non‐treated boys (<a href="./references#CD010899-bbs2-0154" title="MatthewsDJ , JamesKA , MillerLA , PandyaS , CampbellKA , CiafaloniE , et al. Use of corticosteroids in a population‐based cohort of boys with duchenne and becker muscular dystrophy. Journal of Child Neurology2010;25(11):1319‐24. [PUBMED: 20207610] ">Matthews 2010</a>; <a href="./references#CD010899-bbs2-0190" title="RicottiV , RidoutDA , ScottE , QuinlivanR , RobbSA , ManzurAY , et al. Long‐term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery, &amp; Psychiatry2013;84(6):698‐705. [PUBMED: 23250964] ">Ricotti 2012</a>). Physicians usually start treatment during the 'plateau phase' of the condition (usually between four and six years of age) (<a href="./references#CD010899-bbs2-0059" title="BushbyK , FinkelR , BirnkrantD J , CaseLE , ClemensPR , CripeL , et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology2010;9(2):177‐89. [PUBMED: 19945914] ">Bushby 2010</a>). Doses of prednisone, prednisolone, or deflazacort are either taken daily, <a href="./references#CD010899-bbs2-0005" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. [PUBMED: 15336688] ">Biggar 2004</a>; <a href="./references#CD010899-bbs2-0089" title="FenichelGM , FlorenceJM , PestronkA , MendellJR , MoxleyRT3rd , GriggsRC , et al. Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology1991;41(12):1874‐7. [PUBMED: 1745340] ">Fenichel 1991</a>; <a href="./references#CD010899-bbs2-0108" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD010899-bbs2-0154" title="MatthewsDJ , JamesKA , MillerLA , PandyaS , CampbellKA , CiafaloniE , et al. Use of corticosteroids in a population‐based cohort of boys with duchenne and becker muscular dystrophy. Journal of Child Neurology2010;25(11):1319‐24. [PUBMED: 20207610] ">Matthews 2010</a>; <a href="./references#CD010899-bbs2-0161" title="MesaLE , DubrovskyAL , CorderiJ , MarcoP , FloresD . Steroids in Duchenne muscular dystrophy ‐ deflazacort trial. Neuromuscular Disorders1991;1(4):261‐6. [PUBMED: 1822804] ">Mesa 1991</a>, or intermittently, <a href="./references#CD010899-bbs2-0079" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. [PUBMED: 12363102] ">Dubowitz 2002</a>; <a href="./references#CD010899-bbs2-0135" title="KinaliM , MercuriE , MainM , MuntoniF , DubowitzV . An effective, low‐dosage, intermittent schedule of prednisolone in the long‐term treatment of early cases of Duchenne dystrophy. Neuromuscular Disorders2002;12 Suppl 1:S169‐74. [PUBMED: 12206813] ">Kinali 2002</a>. Treatment that is continued after the loss of ambulation may preserve upper body strength, respiratory and cardiac function, and delay the onset of scoliosis (<a href="./references#CD010899-bbs2-0035" title="BalabanB , MatthewsDJ , ClaytonGH , CarryT . Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long‐term effect. American Journal of Physical Medicine &amp; Rehabilitation2005;84(11):843‐50. [PUBMED: 16244521] ">Balaban 2005</a>; <a href="./references#CD010899-bbs2-0005" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. [PUBMED: 15336688] ">Biggar 2004</a>; <a href="./references#CD010899-bbs2-0046" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. [PUBMED: 16545568] ">Biggar 2006</a>; <a href="./references#CD010899-bbs2-0068" title="DaftaryAS , CrisantiM , KalraM , WongB , AminR . Effect of long‐term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics2007;119(2):e320‐4. [PUBMED: 17272595] ">Daftary 2007</a>; <a href="./references#CD010899-bbs2-0122" title="HusseinG , MansourL , GhafarHA , MostafaFA , FawazL . Short‐term effects of corticosteroid therapy on cardiac and skeletal muscles in muscular dystrophies. Journal of Investigative Medicine2014;62(6):875‐9. [PUBMED: 24866459] ">Hussein 2014</a>; <a href="./references#CD010899-bbs2-0136" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC , et al. Orthopedic outcomes of long‐term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. [PUBMED: 17485648] ">King 2007</a>; <a href="./references#CD010899-bbs2-0140" title="LebelDE , CorstonJA , McAdamLC , BiggarWD , AlmanBA . Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long‐term follow‐up. The Journal of Bone &amp; Joint Surgery. American Volume2013;95(12):1057‐61. [PUBMED: 23783200] ">Lebel 2013</a>; <a href="./references#CD010899-bbs2-0151" title="ManzurAY , KuntzerT , PikeM , SwanA . Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003725.pub3; PUBMED: 18254031] ">Manzur 2008</a>; <a href="./references#CD010899-bbs2-0198" title="SchramG , FournierA , LeducH , DahdahN , TherienJ , VanasseM , et al. All‐cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. Journal of the American College of Cardiology2013;61(9):948‐54. [PUBMED: 23352781] ">Schram 2013</a>). Corticosteroids have significant side‐effects, which require proactive management (<a href="./references#CD010899-bbs2-0028" title="AngeliniC . The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle &amp; Nerve2007;36(4):424‐35. [PUBMED: 17541998] ">Angelini 2007</a>; <a href="./references#CD010899-bbs2-0035" title="BalabanB , MatthewsDJ , ClaytonGH , CarryT . Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long‐term effect. American Journal of Physical Medicine &amp; Rehabilitation2005;84(11):843‐50. [PUBMED: 16244521] ">Balaban 2005</a>; <a href="./references#CD010899-bbs2-0046" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. [PUBMED: 16545568] ">Biggar 2006</a>; <a href="./references#CD010899-bbs2-0052" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. [PUBMED: 10951436] ">Bonifati 2000</a>; <a href="./references#CD010899-bbs2-0058" title="BushbyK , MuntoniF , UrtizbereaA , HughesR , GriggsR . Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2‐4 April 2004, Naarden, The Netherlands. Neuromuscular Disorders2004; Vol. 14, issue 8‐9:526‐34. [PUBMED: 15336694] ">Bushby 2004</a>; <a href="./references#CD010899-bbs2-0059" title="BushbyK , FinkelR , BirnkrantD J , CaseLE , ClemensPR , CripeL , et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology2010;9(2):177‐89. [PUBMED: 19945914] ">Bushby 2010</a>; <a href="./references#CD010899-bbs2-0117" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. [PUBMED: 18279756] ">Houde 2008</a>; <a href="./references#CD010899-bbs2-0136" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC , et al. Orthopedic outcomes of long‐term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. [PUBMED: 17485648] ">King 2007</a>; <a href="./references#CD010899-bbs2-0151" title="ManzurAY , KuntzerT , PikeM , SwanA . Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003725.pub3; PUBMED: 18254031] ">Manzur 2008</a>; <a href="./references#CD010899-bbs2-0154" title="MatthewsDJ , JamesKA , MillerLA , PandyaS , CampbellKA , CiafaloniE , et al. Use of corticosteroids in a population‐based cohort of boys with duchenne and becker muscular dystrophy. Journal of Child Neurology2010;25(11):1319‐24. [PUBMED: 20207610] ">Matthews 2010</a>; <a href="./references#CD010899-bbs2-0160" title="MerliniL , GennariM , MalaspinaE , CecconiI , ArmaroliA , GnudiS , et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14‐year follow‐up. Muscle &amp; Nerve2012;45(6):796‐802. [PUBMED: 22581531] ">Merlini 2012</a>; <a href="./references#CD010899-bbs2-0164" title="MoxleyRT3rd , PandyaS , CiafaloniE , FoxDJ , CampbellK . Change in natural history of Duchenne muscular dystrophy with long‐term corticosteroid treatment: implications for management. Journal of Child Neurology2010;25(9):1116‐29. [PUBMED: 20581335] ">Moxley 2010</a>). One such side‐effect is corticosteroid‐induced osteoporosis, which includes the increased risk of vertebral fractures (<a href="./references#CD010899-bbs2-0029" title="AngeliniC , PeterleE . Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myologica2012;31(1):9‐15. [PUBMED: 22655511] ">Angelini 2012</a>; <a href="./references#CD010899-bbs2-0032" title="BachrachLK . Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscular Disorders2005;15(1):86‐7. [PUBMED: 15639126] ">Bachrach 2005</a>; <a href="./references#CD010899-bbs2-0035" title="BalabanB , MatthewsDJ , ClaytonGH , CarryT . Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long‐term effect. American Journal of Physical Medicine &amp; Rehabilitation2005;84(11):843‐50. [PUBMED: 16244521] ">Balaban 2005</a>; <a href="./references#CD010899-bbs2-0055" title="BothwellJE , GordonKE , DooleyJM , MacSweenJ , CummingsEA , SalisburyS . Vertebral fractures in boys with Duchenne muscular dystrophy. Clinical Pediatrics2003;42(4):353‐6. [PUBMED: 12800730] ">Bothwell 2003</a>; <a href="./references#CD010899-bbs2-0041" title="BianchiM L , MazzantiA , GalbiatiE , SaraifogerS , DubiniA , CornelioF , et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporosis International2003;14(9):761‐7. [PUBMED: 12897980] ">Bianchi 2003</a>; <a href="./references#CD010899-bbs2-0060" title="CanalisE , BilezikianJP , AngeliA , GiustinaA . Perspectives on glucocorticoid‐induced osteoporosis. Bone2004;34(4):593‐8. [PUBMED: 15050888] ">Canalis 2004</a>; <a href="./references#CD010899-bbs2-0117" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. [PUBMED: 18279756] ">Houde 2008</a>; <a href="./references#CD010899-bbs2-0136" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC , et al. Orthopedic outcomes of long‐term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. [PUBMED: 17485648] ">King 2007</a>; <a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>; <a href="./references#CD010899-bbs2-0183" title="QuinlivanR , ShawN , BushbyK . 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27‐29 November 2009, Naarden, The Netherlands. Neuromuscular disorders2010;20(11):761‐9. ">Quinlivan 2010</a>; <a href="./references#CD010899-bbs2-0209" title="SöderpalmAC , MagnussonP , AhlanderAC , KarlssonJ , KroksmarkAK , TuliniusM , et al. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscular Disorders2007;17(11‐12):919‐28. [PUBMED: 17627820] ">Soderpalm 2007</a>; <a href="./references#CD010899-bbs2-0225" title="VanStaaTP , LaanRF , BartonIP , CohenS , ReidDM , CooperC . Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis &amp; Rheumatism2003;48(11):3224‐9. [PUBMED: 14613287] ">Van Staa 2003</a>; <a href="./references#CD010899-bbs2-0239" title="WeldonD . The effects of corticosteroids on bone growth and bone density. Annals of Allergy, Asthma &amp; Immunology2009;103(1):3‐11. [PUBMED: 19663120] ">Weldon 2009</a>). </p> </section> <section id="CD010899-sec-0025"> <h4 class="title">Osteoporosis</h4> <p>Osteoporosis is a progressive, systemic skeletal disease, characterised by reduced bone mass and micro‐architectural deterioration of bone tissue. As a result, bone is increasingly fragile and more susceptible to fracture (<a href="./references#CD010899-bbs2-0169" title="NICE (National Institute for Health and Clinical Excellence) 2012. Osteoporosis: assessing the risk of fragility fracture. NICE guideline (CG146). www.nice.org.uk/guidance/cg146/chapter/introduction (accessed 14 June 2016). ">NICE 2012</a>). Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. Osteoporotic fragility fractures are defined as fractures associated with low bone mineral density and include spine, forearm, hip, and shoulder fractures. </p> <p>In children and adolescents, osteoporosis is defined as low bone mineral content or bone mineral density for chronological age. The diagnosis of osteoporosis requires the presence of both a clinically significant fracture history, for example, vertebral compression fracture or long‐bone fractures, and low bone mineral content or bone mineral density. Low bone mineral content or bone mineral density is defined as bones with a Z‐score that is less than or equal to ‐2.0, adjusted for age, gender, and body size, as appropriate (<a href="./references#CD010899-bbs2-0124" title="RauchF , PlotkinH , DiMeglioL , EngelbertRH , HendersonRC , MunnsC , et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. Journal of Clinical Densitometry2008;11(1):22‐8. ">ISCD 2007</a>). </p> <p>Bone mineral content and bone mineral density are assessed in children by dual‐energy X‐ray absorptiometry (DXA) (<a href="./references#CD010899-bbs2-0042" title="BianchiML , BaimS , BishopNJ , GordonCM , HansDB , LangmanCB , et al. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatric Nephrology2010; Vol. 25, issue 1:37‐47. [PUBMED: 19603190] ">Bianchi 2010</a>). Quantitative‐computed tomography, peripheral quantitative‐computed tomography, quantitative ultrasonography, or magnetic resonance imaging (MRI) are also used (<a href="./references#CD010899-bbs2-0033" title="BachrachLK , SillsIN . Clinical report—bone densitometry in children and adolescents. Pediatrics2011;127(1):189‐94. [PUBMED: 21187316] ">Bachrach 2011</a>; <a href="./references#CD010899-bbs2-0057" title="BucknerJL , BowdenSA , MahanJD . Optimizing bone health in Duchenne Muscular Dystrophy. International Journal of Endocrinology2015;2015:928385. [PUBMED: 26124831] ">Buckner 2015</a>). To avoid incorrect estimations, conventional DXA measurements are adjusted according to size for use in children, those with deteriorating bone, and people of shorter stature (<a href="./references#CD010899-bbs2-0044" title="BianchiML , LeonardMB , BechtoldS , HöglerW , MughalMZ , SchönauE , et al. Bone health in children and adolescents with chronic diseases that may affect the skeleton: the 2013 ISCD Pediatric Official Positions. Journal of Clinical Densitometry2014;17(2):281‐94. [PUBMED: 24656723] ">Bianchi 2014</a>). Bone mineral density is measured as age‐based and height‐adjusted Z‐scores (<a href="./references#CD010899-bbs2-0033" title="BachrachLK , SillsIN . Clinical report—bone densitometry in children and adolescents. Pediatrics2011;127(1):189‐94. [PUBMED: 21187316] ">Bachrach 2011</a>; <a href="./references#CD010899-bbs2-0034" title="BaimS , LeonardMB , BianchiML , HansDB , KalkwarfHJ , LangmanCB , et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. Journal of Clinical Densitometry2008;11(1):6‐21. [PUBMED: 18442749] ">Baim 2008</a>; <a href="./references#CD010899-bbs2-0042" title="BianchiML , BaimS , BishopNJ , GordonCM , HansDB , LangmanCB , et al. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatric Nephrology2010; Vol. 25, issue 1:37‐47. [PUBMED: 19603190] ">Bianchi 2010</a>; <a href="./references#CD010899-bbs2-0067" title="CrabtreeNJ , ArabiA , BachrachLK , FewtrellM , El‐Hajj FuleihanG , KecskemethyHH , et al. Dual‐energy X‐ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. Journal of Clinical Densitometry2014;17(2):225‐42. [PUBMED: 24690232] ">Crabtree 2014</a>; <a href="./references#CD010899-bbs2-0092" title="FewtrellMS , British Paediatric &amp; Adolescent Bone Group. Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Archives of Disease in Childhood2003;88(9):795‐8. [PUBMED: 12937102] ">Fewtrell 2003</a>). DXA can also predict the risk of fractures before they occur. Its use is based on a relationship between low bone mineral density and risk of fracture in adults, which also exists in children (<a href="./references#CD010899-bbs2-0063" title="ClarkEM , NessAR , BishopNJ , TobiasJH . Association between bone mass and fractures in children: a prospective cohort study. Journal of Bone and Mineral Research2006;21(9):1489‐95. [PUBMED: 16939408] ">Clark 2006</a>; <a href="./references#CD010899-bbs2-0102" title="GouldingA , CannanR , WilliamsSM , GoldEJ , TaylorRW , Lewis‐BarnedNJ . Bone mineral density in girls with forearm fractures. Journal of Bone and Mineral Research1998;13(1):143‐8. [PUBMED: 9443800] ">Goulding 1998</a>). This is an important application of DXA in patients with DMD, as part of bone health evaluation (<a href="./references#CD010899-bbs2-0043" title="BianchiML , BiggarD , BushbyK , RogolAD , RutterMM , TsengB . Endocrine aspects of Duchenne muscular dystrophy. Neuromuscular Disorders2011; Vol. 21, issue 4:298‐303. [PUBMED: 21353552] ">Bianchi 2011a</a>). </p> <p>Bone is a living tissue, which bone formation and bone resorption constantly remodels (<a href="./references#CD010899-bbs2-0129" title="JoyceNC , HacheLP , ClemensPR . Bone health and associated metabolic complications in neuromuscular diseases. Physical Medicine and Rehabilitation Clinics of North America2012;23(4):773‐99. [PUBMED: 23137737] ">Joyce 2012</a>). Factors that affect bone health include genetics, nutrition, physical activity (loading), age, and hormones. Corticosteroid treatment affects endocrine function, suppressing growth, delaying puberty, reducing bone mineral density, and increasing body weight (<a href="./references#CD010899-bbs2-0043" title="BianchiML , BiggarD , BushbyK , RogolAD , RutterMM , TsengB . Endocrine aspects of Duchenne muscular dystrophy. Neuromuscular Disorders2011; Vol. 21, issue 4:298‐303. [PUBMED: 21353552] ">Bianchi 2011a</a>; <a href="./references#CD010899-bbs2-0076" title="DooleyJM , BobbittSA , CummingsEA . The impact of deflazacort on puberty in Duchenne muscular dystrophy. Pediatric Neurology2013;49(4):292‐3. [PUBMED: 23921283] ">Dooley 2013</a>; <a href="./references#CD010899-bbs2-0244" title="WoodCL , StraubV , GuglieriM , BushbyK , CheethamT . Short stature and pubertal delay in Duchenne muscular dystrophy. Archives of Disease in Childhood 2015 Jul 3 [Epub ahead of print]. [PUBMED: 26141541] ">Wood 2015</a>). Corticosteroids induce bone loss by hindering bone formation through osteoblastic apoptosis (the death of cells that make bone) and by stimulating bone mineral resorption through an increase in the number of osteoclasts (cells that break down bone) (<a href="./references#CD010899-bbs2-0181" title="PoppAW , IseneggerJ , BuergiEM , BuergiU , LippunerK . Glucocorticosteroid‐induced spinal osteoporosis: scientific update on pathophysiology and treatment. European Spine Journal2006;15(7):1035‐49. [PUBMED: 16474946] ">Popp 2006</a>). The reduction in bone mineral density from changes in bone metabolism is not fully understood (<a href="./references#CD010899-bbs2-0043" title="BianchiML , BiggarD , BushbyK , RogolAD , RutterMM , TsengB . Endocrine aspects of Duchenne muscular dystrophy. Neuromuscular Disorders2011; Vol. 21, issue 4:298‐303. [PUBMED: 21353552] ">Bianchi 2011a</a>). Deficiencies in testosterone (delayed puberty) and growth hormone, or resistance to an insulin‐like growth hormone, and limited mobility with excessive weight gain contribute to a reduction in bone mineral density (<a href="./references#CD010899-bbs2-0023" title="AllenDB , JuliusJR , BreenTJ , AttieKM . Treatment of glucocorticoid‐induced growth suppression with growth hormone. National Cooperative Growth Study. The Journal of Clinical Endocrinology and Metabolism1998;83(8):2824‐9. [PUBMED: 9709954] ">Allen 1998</a>; <a href="./references#CD010899-bbs2-0043" title="BianchiML , BiggarD , BushbyK , RogolAD , RutterMM , TsengB . Endocrine aspects of Duchenne muscular dystrophy. Neuromuscular Disorders2011; Vol. 21, issue 4:298‐303. [PUBMED: 21353552] ">Bianchi 2011a</a>; <a href="./references#CD010899-bbs2-0076" title="DooleyJM , BobbittSA , CummingsEA . The impact of deflazacort on puberty in Duchenne muscular dystrophy. Pediatric Neurology2013;49(4):292‐3. [PUBMED: 23921283] ">Dooley 2013</a>). Bone mineral density is difficult to assess in DMD due to lack of normative curves, short stature, delayed bone age, etc. Corticosteroid treatment may not appear to reduce bone mineral density to the same extent as in adults. <a href="./references#CD010899-bbs2-0210" title="SöderpalmAC , MagnussonP , AhlanderAC , KarlssonJ , KroksmarkAK , TuliniusM , et al. Bone markers and bone mineral density in Duchenne muscular dystrophy. Journal of Musculoskeletal &amp; Neuronal Interactions2008;8(1):24. [PUBMED: 18398258] ">Soderpalm 2008</a> commented that lower bone mineral density in boys with DMD is likely to be the combined result of corticosteroid treatment, muscle loss from the disease, and reduced mobility. Low bone mineral density increases the risk of bone fragility fractures (<a href="./references#CD010899-bbs2-0032" title="BachrachLK . Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. Neuromuscular Disorders2005;15(1):86‐7. [PUBMED: 15639126] ">Bachrach 2005</a>; <a href="./references#CD010899-bbs2-0077" title="DouvillezB , BraillonP , HodgkinsonI , BerardC . [Pain, osteopenia and body composition of 22 patients with Duchenne muscular dystrophy: a descriptive study]. Annales de Readaptation et de Medecine Physique2005;48(8):616‐22. [PUBMED: 16023755] ">Douvillez 2005</a>; <a href="./references#CD010899-bbs2-0129" title="JoyceNC , HacheLP , ClemensPR . Bone health and associated metabolic complications in neuromuscular diseases. Physical Medicine and Rehabilitation Clinics of North America2012;23(4):773‐99. [PUBMED: 23137737] ">Joyce 2012</a>; <a href="./references#CD010899-bbs2-0182" title="QuinlivanR , RoperH , DavieM , ShawNJ , McDonaghJ , BushbyK . Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscular Disorders2005; Vol. 15, issue 1:72‐9. [PUBMED: 15639124] ">Quinlivan 2005</a>; <a href="./references#CD010899-bbs2-0219" title="TalimB , MalagutiC , GnudiS , PolitanoL , MerliniL . Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscular Disorders2002;12(3):294‐5. [PUBMED: 11801403] ">Talim 2002</a>). There are some data to suggest that boys with DMD who are corticosteroid‐naive (that is, those who have not previously been exposed to corticosteroids) are at increased risk of long‐bone fractures (<a href="./references#CD010899-bbs2-0046" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. [PUBMED: 16545568] ">Biggar 2006</a>; <a href="./references#CD010899-bbs2-0105" title="GranataC , GianniniS , VillaD , Bonfiglioli StagniS , MerliniL . Fractures in myopathies. La Chirurgia degli Organi di Movimento1991;76(1):39‐45. [PUBMED: 1893785] ">Granata 1991</a>; <a href="./references#CD010899-bbs2-0117" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. [PUBMED: 18279756] ">Houde 2008</a>; <a href="./references#CD010899-bbs2-0118" title="HsuJD . Extremity fractures in children with neuromuscular disease. The Johns Hopkins Medical Journal1979;145(3):89‐93. [PUBMED: 470294] ">Hsu 1979</a>; <a href="./references#CD010899-bbs2-0139" title="LarsonCM , HendersonRC . Bone mineral density and fractures in boys with Duchenne muscular dystrophy. Journal of Pediatric Orthopedics2000;20(1):71‐4. [PUBMED: 10641693] ">Larson 2000</a>; <a href="./references#CD010899-bbs2-0157" title="McDonaldDG , KinaliM , GallagherAC , MercuriE , MuntoniF , RoperH , et al. Fracture prevalence in Duchenne muscular dystrophy. Developmental Medicine &amp; Child Neurology2002;44(10):695‐8. [PUBMED: 12418795] ">McDonald 2002</a>; <a href="./references#CD010899-bbs2-0228" title="VestergaardP , GlerupH , SteffensenBF , RejnmarkL , RahbekJ , MoseklideL . Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. Journal of Rehabilitation Medicine2001;33(4):150‐5. ">Vestergaard 2001</a>), implying that corticosteroids are not the only cause for these fractures and causation is complex. </p> </section> <section id="CD010899-sec-0026"> <h4 class="title">Osteoporotic fragility fractures</h4> <p>Vertebral fragility fractures are recognised as the most common manifestation of corticosteroid‐induced osteoporosis (<a href="./references#CD010899-bbs2-0022" title="Al‐OsailAM , Sadat‐AliM , Al‐ElqAH , Al‐OmranAS , AzzamQ . Glucocorticoid‐related osteoporotic fractures. Singapore Medical Journal2010;51(12):948‐51. [PUBMED: 21221500] ">Al‐Osail 2010</a>; <a href="./references#CD010899-bbs2-0191" title="RoddC , LangB , RamsayT , AlosN , HuberAM , CabralDA , et al. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care &amp; Research2012;64(1):122‐31. [PUBMED: 22213727] ">Rodd 2012</a>; <a href="./references#CD010899-bbs2-0216" title="SugiyamaT , SuzukiS , YoshidaT , MayamaT , HashimotoN , SuyamaK , et al. Age, initial dose and dose increase are independent risk factors for symptomatic vertebral fractures in glucocorticoid‐treated male patients. Internal Medicine2011;50(8):817‐24. [PUBMED: 21498928] ">Sugiyama 2011</a>; <a href="./references#CD010899-bbs2-0223" title="vanStaaTP , LeufkensHG , AbenhaimL , ZhangB , CooperC . Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology2000;39(12):1383‐9. [PUBMED: 11136882] ">Van Staa 2000</a>; <a href="./references#CD010899-bbs2-0224" title="vanStaaTP , AbenhaimL , CooperC , ZhangB , LeufkensHG . Public health impact of adverse bone effects of oral corticosteroids. British Journal of Clinical Pharmacology2001;51(6):601‐7. [PUBMED: 11422020] ">Van Staa 2001</a>; <a href="./references#CD010899-bbs2-0225" title="VanStaaTP , LaanRF , BartonIP , CohenS , ReidDM , CooperC . Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis &amp; Rheumatism2003;48(11):3224‐9. [PUBMED: 14613287] ">Van Staa 2003</a>; <a href="./references#CD010899-bbs2-0227" title="VaronosS , AnsellBM , ReeveJ . Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy. Calcified Tissue International1987;41(2):75‐8. [PUBMED: 3115548] ">Varonos 1987</a>). Vertebral fragility fractures have not been reported in corticosteroid‐naive patients with DMD of any age (<a href="./references#CD010899-bbs2-0025" title="AlmanBA , RazaSN , BiggarWD . Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. The Journal of Bone &amp; Joint Surgery2004;86‐A(3):519‐24. [PUBMED: 14996877] ">Alman 2004</a>; <a href="./references#CD010899-bbs2-0117" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. [PUBMED: 18279756] ">Houde 2008</a>; <a href="./references#CD010899-bbs2-0136" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC , et al. Orthopedic outcomes of long‐term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. [PUBMED: 17485648] ">King 2007</a>), and very often, vertebral fractures are not tracked in children with DMD (especially those not treated with steroids). In boys with DMD taking corticosteroids, the occurrence of vertebral fractures ranges from 15% to 75% after a mean duration of 6.3 years on treatment (ranging from 4.5 to 8.0 years) (<a href="./references#CD010899-bbs2-0055" title="BothwellJE , GordonKE , DooleyJM , MacSweenJ , CummingsEA , SalisburyS . Vertebral fractures in boys with Duchenne muscular dystrophy. Clinical Pediatrics2003;42(4):353‐6. [PUBMED: 12800730] ">Bothwell 2003</a>; <a href="./references#CD010899-bbs2-0117" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. [PUBMED: 18279756] ">Houde 2008</a>; <a href="./references#CD010899-bbs2-0136" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC , et al. Orthopedic outcomes of long‐term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. [PUBMED: 17485648] ">King 2007</a>; <a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>). The incidence of long‐bone fractures was, however, similar in treated and untreated patients (<a href="./references#CD010899-bbs2-0117" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. [PUBMED: 18279756] ">Houde 2008</a>; <a href="./references#CD010899-bbs2-0157" title="McDonaldDG , KinaliM , GallagherAC , MercuriE , MuntoniF , RoperH , et al. Fracture prevalence in Duchenne muscular dystrophy. Developmental Medicine &amp; Child Neurology2002;44(10):695‐8. [PUBMED: 12418795] ">McDonald 2002</a>) (24% and 26%, respectively, in <a href="./references#CD010899-bbs2-0117" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. [PUBMED: 18279756] ">Houde 2008</a>). </p> <p>Those treated with corticosteroids tend to be more ambulant, and patients who are more ambulant are more likely to fall and sustain a long‐bone fracture. Non‐ambulatory patients appear to be at an increased risk of vertebral fractures (<a href="./references#CD010899-bbs2-0139" title="LarsonCM , HendersonRC . Bone mineral density and fractures in boys with Duchenne muscular dystrophy. Journal of Pediatric Orthopedics2000;20(1):71‐4. [PUBMED: 10641693] ">Larson 2000</a>; <a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>). Previous surgical intervention for scoliosis may also prevent vertebral fragility fractures (<a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>). Lack of ambulation, taking steroids previously, or both, may lead to a greater body fat composition in patients with DMD. Body fat percentage was reported as significantly higher in patients with vertebral fractures (47.8% ± 12%) than in those with long‐bone fractures (33% ± 14.2%) (P &lt; 0.05) (<a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>). </p> <p>Vertebral fractures can be symptomatic or asymptomatic. Acute back pain is closely associated with symptomatic vertebral fragility fractures (odds ratio (OR) 10.6, 95% confidence interval (CI) 2.1 to 53.8, P = 0.004) and requires radiological investigation to confirm the diagnosis (<a href="./references#CD010899-bbs2-0119" title="HuberAM , GabouryI , CabralDA , LangB , NiA , StephureD , et al. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders. Arthritis Care &amp; Research2010;62(4):516‐26. [PUBMED: 20391507] ">Huber 2010</a>; <a href="./references#CD010899-bbs2-0219" title="TalimB , MalagutiC , GnudiS , PolitanoL , MerliniL . Vertebral compression in Duchenne muscular dystrophy following deflazacort. Neuromuscular Disorders2002;12(3):294‐5. [PUBMED: 11801403] ">Talim 2002</a>), but an estimated 20% of vertebral fractures are asymptomatic (<a href="./references#CD010899-bbs2-0152" title="ManzurAY , ScottE , MunotP , VijaykumarK , Muntoni F on behalf of UK NorthStar Clinical Network. UK NorthStar Neuromuscular Clinical Network (NSCN): National audit results in Duchenne muscular dystrophy (DMD) corticosteroid practice, vitamin D status and bone health. Neuromuscular Disorders2010;20(S1):S8. ">Manzur 2010</a>). Asymptomatic fractures are thought to be precursors of painful symptomatic fragility fractures (<a href="./references#CD010899-bbs2-0144" title="LeungDG , Germain‐LeeEL , DengerBE , WagnerKR . Report on the Second Endocrine Aspects Of Duchenne muscular dystrophy Conference December 1‐2, 2010, Baltimore, Maryland, USA. Neuromuscular Disorders2011; Vol. 21, issue 8:594‐601. [PUBMED: 21763136] ">Leung 2011</a>). Asymptomatic fractures may be undetected because radiological or densitometric monitoring is not conducted routinely (<a href="./references#CD010899-bbs2-0183" title="QuinlivanR , ShawN , BushbyK . 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27‐29 November 2009, Naarden, The Netherlands. Neuromuscular disorders2010;20(11):761‐9. ">Quinlivan 2010</a>). Diagnosis and confirmation of a vertebral fracture requires visual examination of lateral X‐ray or magnetic resonance imaging (MRI) images to assess the change in shape of the vertebrae as biconcave, wedge, or crush, as well as the degree of deformity (<a href="./references#CD010899-bbs2-0099" title="GenantHK , WuCY , vanKuijkC , NevittMC . Vertebral fracture assessment using a semiquantitative technique. Journal of Bone and Mineral Research1993;8(9):1137‐48. [PUBMED: 8237484] ">Genant 1993</a>; <a href="./references#CD010899-bbs2-0143" title="LenchikL , RogersLF , DelmasPD , GenantHK . Diagnosis of osteoporotic vertebral fractures: importance of recognition and description by radiologists. AJR American Journal of Roentgenology2004;183(4):949‐58. [PUBMED: 15385286] ">Lenchik 2004</a>; <a href="./references#CD010899-bbs2-0183" title="QuinlivanR , ShawN , BushbyK . 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27‐29 November 2009, Naarden, The Netherlands. Neuromuscular disorders2010;20(11):761‐9. ">Quinlivan 2010</a>). </p> <p>The occurrence of fractures is significantly related to low bone mineral density in DMD (<a href="./references#CD010899-bbs2-0030" title="AparicioLF , JurkovicM , DeLulloJ . Decreased bone density in ambulatory patients with Duchenne muscular dystrophy. Journal of Pediatric Orthopedics2002;22(2):179‐81. [PUBMED: 11856925] ">Aparicio 2002</a>; <a href="./references#CD010899-bbs2-0134" title="KhatriIA , ChaudhryUS , SeikalyMG , BrowneRH , IannacconeST . Low bone mineral density in spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2008;10(1):11‐7. [PUBMED: 18772695] ">Khatri 2008</a>; <a href="./references#CD010899-bbs2-0139" title="LarsonCM , HendersonRC . Bone mineral density and fractures in boys with Duchenne muscular dystrophy. Journal of Pediatric Orthopedics2000;20(1):71‐4. [PUBMED: 10641693] ">Larson 2000</a>). Bone mineral density is often lower than normal for the age of the patient (<a href="./references#CD010899-bbs2-0041" title="BianchiM L , MazzantiA , GalbiatiE , SaraifogerS , DubiniA , CornelioF , et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporosis International2003;14(9):761‐7. [PUBMED: 12897980] ">Bianchi 2003</a>; <a href="./references#CD010899-bbs2-0066" title="CrabtreeNJ , RoperH , McMurchieH , ShawNJ . Regional changes in bone area and bone mineral content in boys with Duchenne muscular dystrophy receiving corticosteroid therapy. The Journal of Pediatrics2010;156(3):450‐5. [PUBMED: 19880140] ">Crabtree 2010</a>; <a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>; <a href="./references#CD010899-bbs2-0211" title="SöderpalmAC , MagnussonP , ÅhlanderAC , KarlssonJ , KroksmarkAK , TuliniusM , et al. Bone mass development in patients with Duchenne and Becker muscular dystrophies: a 4‐year clinical follow‐up. Acta Paediatrica2012;101(4):424‐32. [PUBMED: 22103559] ">Soderpalm 2012</a>). In children and adolescents with DMD, the baseline bone mineral density is low due to lack of weight‐bearing activity. It is probably lowered further by corticosteroids. While some studies have shown no reduction in spinal bone mineral density after 30 months of corticosteroid therapy for DMD in prepubertal boys (<a href="./references#CD010899-bbs2-0066" title="CrabtreeNJ , RoperH , McMurchieH , ShawNJ . Regional changes in bone area and bone mineral content in boys with Duchenne muscular dystrophy receiving corticosteroid therapy. The Journal of Pediatrics2010;156(3):450‐5. [PUBMED: 19880140] ">Crabtree 2010</a>), or only a marginal reduction in children and adolescents taking corticosteroids (<a href="./references#CD010899-bbs2-0006" title="CohranVC , GriffithsM , HeubiJE . Bone mineral density in children exposed to chronic glucocorticoid therapy. Clinical Pediatrics2008;47(5):469‐75. [PUBMED: 18378941] ">Cohran 2008</a>), others reported a substantially lowered bone mineral density in boys (children and adolescents) taking corticosteroids, particularly those with reduced mobility (<a href="./references#CD010899-bbs2-0041" title="BianchiM L , MazzantiA , GalbiatiE , SaraifogerS , DubiniA , CornelioF , et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporosis International2003;14(9):761‐7. [PUBMED: 12897980] ">Bianchi 2003</a>; <a href="./references#CD010899-bbs2-0009" title="HawkerGA , RidoutR , HarrisVA , ChaseCC , FieldingLJ , BiggarWD . Alendronate in the treatment of low bone mass in steroid‐treated boys with Duchennes muscular dystrophy. Archives of Physical Medicine and Rehabilitation2005;86(2):284‐8. [PUBMED: 15706555] ">Hawker 2005</a>; <a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>). </p> <p>International consensus workshops have taken place to prioritise poor bone health in DMD patients and to improve clinical outcomes through education (<a href="./references#CD010899-bbs2-0045" title="BiggarWD , BachrachLK , HendersonRC , KalkwarfH , PlotkinH , WongBL . Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscular Disorders2005; Vol. 15, issue 1:80‐5. [PUBMED: 15639125] ">Biggar 2005</a>; <a href="./references#CD010899-bbs2-0144" title="LeungDG , Germain‐LeeEL , DengerBE , WagnerKR . Report on the Second Endocrine Aspects Of Duchenne muscular dystrophy Conference December 1‐2, 2010, Baltimore, Maryland, USA. Neuromuscular Disorders2011; Vol. 21, issue 8:594‐601. [PUBMED: 21763136] ">Leung 2011</a>; <a href="./references#CD010899-bbs2-0167" title="MuntoniF , BushbyK , ManzurAY . Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy 24 January 2005, London, UK. Neuromuscular Disorders2006;16(3):210‐9. [PUBMED: 16497502] ">Muntoni 2006</a>; <a href="./references#CD010899-bbs2-0182" title="QuinlivanR , RoperH , DavieM , ShawNJ , McDonaghJ , BushbyK . Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscular Disorders2005; Vol. 15, issue 1:72‐9. [PUBMED: 15639124] ">Quinlivan 2005</a>; <a href="./references#CD010899-bbs2-0183" title="QuinlivanR , ShawN , BushbyK . 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27‐29 November 2009, Naarden, The Netherlands. Neuromuscular disorders2010;20(11):761‐9. ">Quinlivan 2010</a>). Recent advances in treatments for muscle loss have enabled people with DMD to actively participate in life for longer. Bone health in patients with DMD is an important issue because long‐bone fractures seriously harm mobility: approximately 20% to 50% of independently mobile patients lose the ability to walk unaided following a long‐bone fracture (<a href="./references#CD010899-bbs2-0139" title="LarsonCM , HendersonRC . Bone mineral density and fractures in boys with Duchenne muscular dystrophy. Journal of Pediatric Orthopedics2000;20(1):71‐4. [PUBMED: 10641693] ">Larson 2000</a>; <a href="./references#CD010899-bbs2-0152" title="ManzurAY , ScottE , MunotP , VijaykumarK , Muntoni F on behalf of UK NorthStar Clinical Network. UK NorthStar Neuromuscular Clinical Network (NSCN): National audit results in Duchenne muscular dystrophy (DMD) corticosteroid practice, vitamin D status and bone health. Neuromuscular Disorders2010;20(S1):S8. ">Manzur 2010</a>; <a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>; <a href="./references#CD010899-bbs2-0157" title="McDonaldDG , KinaliM , GallagherAC , MercuriE , MuntoniF , RoperH , et al. Fracture prevalence in Duchenne muscular dystrophy. Developmental Medicine &amp; Child Neurology2002;44(10):695‐8. [PUBMED: 12418795] ">McDonald 2002</a>; <a href="./references#CD010899-bbs2-0228" title="VestergaardP , GlerupH , SteffensenBF , RejnmarkL , RahbekJ , MoseklideL . Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. Journal of Rehabilitation Medicine2001;33(4):150‐5. ">Vestergaard 2001</a>). Identifying treatment strategies to prevent corticosteroid‐induced osteoporosis and prevent often painful fragility fractures in DMD may have a significant effect in improving quality of life for these patients. </p> </section> </section> <section id="CD010899-sec-0027"> <h3 class="title" id="CD010899-sec-0027">Description of the intervention</h3> <p>The following pharmacological and non‐pharmacological interventions are thought to have the potential to prevent or treat corticosteroid‐induced osteoporosis by increasing bone mineral density and reduce the risk of fractures in patients with DMD. </p> <section id="CD010899-sec-0028"> <h4 class="title">Bisphosphonates</h4> <p>Intravenous bisphosphonates are used to treat painful vertebral fractures in boys with DMD and are associated with improvements in back pain (<a href="./references#CD010899-bbs2-0012" title="SbrocchiAM , RauchF , JacobP , McCormickA , McMillanHJ , MatzingerMA , et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporosis International2012;23(11):2703‐11. [PUBMED: 22297733] ">Sbrocchi 2012</a>). The use of bisphosphonate treatment in children is relatively new, but there are growing numbers of trials suggesting benefit, particularly in children with osteogenesis imperfecta (bone fragility) (<a href="./references#CD010899-bbs2-0024" title="AllingtonN , VivegnisD , GerardP . Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthopaedica Belgica2005;71(1):91‐7. [PUBMED: 15792214] ">Allington 2005</a>; <a href="./references#CD010899-bbs2-0040" title="BianchiML , CimazR , BardareM , ZulianF , LeporeL , BoncompagniA , et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis &amp; Rheumatism2000;43(9):1960‐6. [PUBMED: 11014345] ">Bianchi 2000</a>; <a href="./references#CD010899-bbs2-0056" title="BrumsenC , HamdyNA , PapapoulosSE . Long‐term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine1997;76(4):266‐83. [PUBMED: 9279333] ">Brumsen 1997</a>; <a href="./references#CD010899-bbs2-0101" title="GlorieuxFH , BishopNJ , PlotkinH , ChabotG , LanoueG , TraversR . Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. The New England Journal of Medicine1998;339(14):947‐52. [PUBMED: 9753709] ">Glorieux 1998</a>; <a href="./references#CD010899-bbs2-0009" title="HawkerGA , RidoutR , HarrisVA , ChaseCC , FieldingLJ , BiggarWD . Alendronate in the treatment of low bone mass in steroid‐treated boys with Duchennes muscular dystrophy. Archives of Physical Medicine and Rehabilitation2005;86(2):284‐8. [PUBMED: 15706555] ">Hawker 2005</a>; <a href="./references#CD010899-bbs2-0112" title="HendersonRC , LarkRK , KecskemethyHH , MillerF , HarckeHT , BachrachSJ . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo‐controlled clinical trial. The Journal of Pediatrics2002;141(5):644‐51. [PUBMED: 12410192] ">Henderson 2002</a>; <a href="./references#CD010899-bbs2-0010" title="HoustonC , MathewsK , Shibli‐RahhalA . Bone density and alendronate effects in Duchenne muscular dystrophy patients. Muscle &amp; Nerve2014;49(4):506‐11. [PUBMED: 23835890] ">Houston 2014</a>; <a href="./references#CD010899-bbs2-0170" title="Palomo AtanceE , Ballester HerreraMJ , Márquez de La PlataMA , Medina CanoE , Carmona VilchezRM . Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy [Alendronato en el tratamiento de la osteoporosis secundaria a la distrofia muscular de Duchenne]. Anales de Pediatria2011;74(2):122‐5. [PUBMED: 21169073] ">Palomo 2011</a>; <a href="./references#CD010899-bbs2-0178" title="PlotkinH , RauchF , BishopNJ , MontpetitK , Ruck‐GibisJ , TraversR , et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. The Journal of Clinical Endocrinology and Metabolism2000;85(5):1846‐50. [PUBMED: 10843163] ">Plotkin 2000</a>; <a href="./references#CD010899-bbs2-0179" title="PlotkinH , CoughlinS , KreikemeierR , HeldtK , BruzoniM , LernerG . Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Developmental Medicine &amp; Child Neurology2006;48(9):709‐12. [PUBMED: 16904014] ">Plotkin 2006</a>; <a href="./references#CD010899-bbs2-0184" title="RauchF , TraversR , PlotkinH , GlorieuxFH . The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. The Journal of Clinical Investigation2002;110(9):1293‐9. [PUBMED: 12417568] ">Rauch 2002</a>; <a href="./references#CD010899-bbs2-0194" title="RudgeS , HailwoodS , HorneA , LucasJ , WuF , CundyT . Effects of once‐weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology2005;44(6):813‐8. [PUBMED: 15695300] ">Rudge 2005</a>; <a href="./references#CD010899-bbs2-0012" title="SbrocchiAM , RauchF , JacobP , McCormickA , McMillanHJ , MatzingerMA , et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporosis International2012;23(11):2703‐11. [PUBMED: 22297733] ">Sbrocchi 2012</a>; <a href="./references#CD010899-bbs2-0204" title="ShawNJ , BoivinCM , CrabtreeNJ . Intravenous pamidronate in juvenile osteoporosis. Archives of Disease in Childhood2000;83(2):143‐5. [PUBMED: 10906023] ">Shaw 2000</a>; <a href="./references#CD010899-bbs2-0207" title="SholasM G , TannB , Gaebler‐SpiraD . Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series. Journal of Pediatric Orthopedics2005;25(3):326‐31. [PUBMED: 15832148] ">Sholas 2005</a>; <a href="./references#CD010899-bbs2-0231" title="WagnerS , PoirotI , VuillerotC , BerardC . Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders. Annals of Physical and Rehabilitation Medicine2011;54(6):348‐58. [PUBMED: 21840280] ">Wagner 2011</a>; <a href="./references#CD010899-bbs2-0236" title="WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. The Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. [PUBMED: 21106710] ">Ward 2011</a>). A randomised controlled trial (RCT) to investigate the efficacy and safety of daily oral alendronate in children and adolescents with osteogenesis imperfecta over two years found that the mean spine area Z‐score increased from ‐4.6 to ‐3.3 compared to ‐4.6 to ‐4.5 in the placebo group. Long‐bone fracture incidence and bone pain were similar between groups (<a href="./references#CD010899-bbs2-0236" title="WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. The Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. [PUBMED: 21106710] ">Ward 2011</a>). </p> <p>Bisphosphonates appear to be well tolerated by children for periods of up to three years (<a href="./references#CD010899-bbs2-0205" title="ShawNJ , BishopNJ . Bisphosphonate treatment of bone disease. Archives of Disease in Childhood2005;90(5):494‐9. [PUBMED: 15851432] ">Shaw 2005</a>; <a href="./references#CD010899-bbs2-0235" title="WardL , TriccoAC , PhuongP , CranneyA , BarrowmanN , GabouryI , et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005324.pub2] ">Ward 2007b</a>). Dosing regimes differ among paediatric studies (<a href="./references#CD010899-bbs2-0235" title="WardL , TriccoAC , PhuongP , CranneyA , BarrowmanN , GabouryI , et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005324.pub2] ">Ward 2007b</a>). Oral bisphosphonates are prescribed according to body weight (mg/kg) (<a href="./references#CD010899-bbs2-0040" title="BianchiML , CimazR , BardareM , ZulianF , LeporeL , BoncompagniA , et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis &amp; Rheumatism2000;43(9):1960‐6. [PUBMED: 11014345] ">Bianchi 2000</a>; <a href="./references#CD010899-bbs2-0009" title="HawkerGA , RidoutR , HarrisVA , ChaseCC , FieldingLJ , BiggarWD . Alendronate in the treatment of low bone mass in steroid‐treated boys with Duchennes muscular dystrophy. Archives of Physical Medicine and Rehabilitation2005;86(2):284‐8. [PUBMED: 15706555] ">Hawker 2005</a>; <a href="./references#CD010899-bbs2-0194" title="RudgeS , HailwoodS , HorneA , LucasJ , WuF , CundyT . Effects of once‐weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology2005;44(6):813‐8. [PUBMED: 15695300] ">Rudge 2005</a>). Intravenous bisphosphonates are usually administered at a dose of 1 mg/kg to 1.5 mg/kg (<a href="./references#CD010899-bbs2-0019" title="AcottPD , WongJA , LangBA , CrockerJF . Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatric Nephrology2005;20(3):368‐73. [PUBMED: 15690187] ">Acott 2005</a>; <a href="./references#CD010899-bbs2-0204" title="ShawNJ , BoivinCM , CrabtreeNJ . Intravenous pamidronate in juvenile osteoporosis. Archives of Disease in Childhood2000;83(2):143‐5. [PUBMED: 10906023] ">Shaw 2000</a>). </p> <p>Treatment is usually combined with vitamin D and calcium supplements to minimise the risk of hypocalcaemia (<a href="./references#CD010899-bbs2-0150" title="MaaloufNM , HellerHJ , OdvinaC V , KimPJ , SakhaeeK . Bisphosphonate‐induced hypocalcemia: report of 3 cases and review of literature. Endocrine Practice2006;12(1):48‐53. [PUBMED: 16524863] ">Maalouf 2006</a>; <a href="./references#CD010899-bbs2-0180" title="PooleKE , CompstonJE . Bisphosphonates in the treatment of osteoporosis. BMJ2012;344:e3211. [PUBMED: 22619192] ">Poole 2012</a>); however, calcium supplements reduce the absorption of bisphosphonates. Adverse effects are more common with intravenous than oral bisphosphonates (<a href="./references#CD010899-bbs2-0213" title="SomaloL , SantosF . Clinical use of bisphosphonates in children. World Journal of Pediatrics2007;3(4):245‐53. ">Somalo 2007</a>). The U.S. Food and Drug Adminstration (FDA) is reviewing long‐term use (<a href="./references#CD010899-bbs2-0088" title="Food , DrugAdministration . Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. September 9, 2011. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf (accessed 21 December 2016). ">FDA 2011</a>). Atypical fractures occurring with prolonged bisphosphonate therapy have been a featured concern in recent publications (<a href="./references#CD010899-bbs2-0064" title="CompstonJ . Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporosis International2011;22(12):2951‐61. [PUBMED: 21997225] ">Compston 2011</a>; <a href="./references#CD010899-bbs2-0082" title="EdwardsMH , McCraeFC , Young‐MinSA . Alendronate‐related femoral diaphysis fracture‐‐what should be done to predict and prevent subsequent fracture of the contralateral side?. Osteoporosis International2010;21(4):701‐3. [PUBMED: 19562241] ">Edwards 2010</a>; <a href="./references#CD010899-bbs2-0100" title="GirgisCM , SeibelMJ . Atypical femur fractures: a complication of prolonged bisphosphonate therapy?. The Medical Journal of Australia2010; Vol. 193, issue 4:196‐8. [PUBMED: 20712536] ">Girgis 2010</a>; <a href="./references#CD010899-bbs2-0123" title="IsaacsJD , ShidiakL , HarrisIA , SzomorZL . Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clinical Orthopaedics and Related Research2010;468(12):3384‐92. [PUBMED: 20809164] ">Isaacs 2010</a>; <a href="./references#CD010899-bbs2-0203" title="ShaneE , BurrD , EbelingPR , AbrahamsenB , AdlerRA , BrownTD , et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research2010;25(11):2267‐94. [PUBMED: 20842676] ">Shane 2010</a>), and there have been cautions that high and prolonged doses may paradoxically induce osteoporosis (<a href="./references#CD010899-bbs2-0240" title="WhyteMP , McAlisterWH , NovackDV , ClementsKL , SchoeneckerPL , WenkertD . Bisphosphonate‐induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. Journal of Bone and Mineral Research2008;23(10):1698‐707. [PUBMED: 18505375] ">Whyte 2008</a>). </p> </section> <section id="CD010899-sec-0029"> <h4 class="title">Calcium</h4> <p>A balanced calcium‐rich diet is recommended as the best long‐term strategy to maintain adequate calcium levels (<a href="./references#CD010899-bbs2-0031" title="BacciottiniL , TaniniA , FalchettiA , MasiL , FranceschelliF , PampaloniB , et al. Calcium bioavailability from a calcium‐rich mineral water, with some observations on method. Journal of Clinical Gastroenterology2004;38(9):761‐6. [PUBMED: 15365401] ">Bacciottini 2004</a>; <a href="./references#CD010899-bbs2-0045" title="BiggarWD , BachrachLK , HendersonRC , KalkwarfH , PlotkinH , WongBL . Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscular Disorders2005; Vol. 15, issue 1:80‐5. [PUBMED: 15639125] ">Biggar 2005</a>; <a href="./references#CD010899-bbs2-0217" title="SunyeczJA . The use of calcium and vitamin D in the management of osteoporosis. Therapeutics and Clinical Risk Management2008;4(4):827‐36. [PUBMED: 19209265] ">Sunyecz 2008</a>). Calcium supplements in healthy children have shown short‐term improvements in bone mineral density (<a href="./references#CD010899-bbs2-0241" title="WinzenbergTM , ShawK , FryerJ , JonesG . Calcium supplementation for improving bone mineral density in children. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005119.pub2] ">Winzenberg 2006</a>). Intestinal calcium absorption is dependent on other factors such as vitamin D levels. </p> <p>Genetics determine 60% to 80% of attained peak bone mass, and environmental factors, such as nutrition, exercise, and disease, determine the remainder (<a href="./references#CD010899-bbs2-0183" title="QuinlivanR , ShawN , BushbyK . 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27‐29 November 2009, Naarden, The Netherlands. Neuromuscular disorders2010;20(11):761‐9. ">Quinlivan 2010</a>). Bone mineral density can vary between individuals from early childhood and be predictive of a potential fracture risk in children with medical conditions affecting bone health (<a href="./references#CD010899-bbs2-0091" title="FerrariS , RizzoliR , SlosmanD , BonjourJP . Familial resemblance for bone mineral mass is expressed before puberty. The Journal of Clinical Endocrinology and Metabolism1998;83(2):358‐61. [PUBMED: 9467541] ">Ferrari 1998</a>; <a href="./references#CD010899-bbs2-0104" title="GouldingA , GrantAM , WilliamsSM . Bone and body composition of children and adolescents with repeated forearm fractures. Journal of Bone and Mineral Research2005;20(12):2090‐6. [PUBMED: 16294262] ">Goulding 2005</a>; <a href="./references#CD010899-bbs2-0111" title="HarveyNC , ColeZA , CrozierSR , KimM , NtaniG , GoodfellowL , et al. Physical activity, calcium intake and childhood bone mineral: a population‐based cross‐sectional study. Osteoporosis International2012;23(1):121‐30. [PUBMED: 21562877] ">Harvey 2012</a>; <a href="./references#CD010899-bbs2-0183" title="QuinlivanR , ShawN , BushbyK . 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27‐29 November 2009, Naarden, The Netherlands. Neuromuscular disorders2010;20(11):761‐9. ">Quinlivan 2010</a>; <a href="./references#CD010899-bbs2-0241" title="WinzenbergTM , ShawK , FryerJ , JonesG . Calcium supplementation for improving bone mineral density in children. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005119.pub2] ">Winzenberg 2006</a>). A review of calcium supplementation for improving bone mineral density in children showed no effect on spinal bone mineral density, but a small effect on total body bone mineral content (BMC) (<a href="./references#CD010899-bbs2-0241" title="WinzenbergTM , ShawK , FryerJ , JonesG . Calcium supplementation for improving bone mineral density in children. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005119.pub2] ">Winzenberg 2006</a>). A double‐blind, placebo‐controlled study of 149 girls showed an increase in bone mineral density in those taking calcium‐supplemented food compared to those who did not (<a href="./references#CD010899-bbs2-0053" title="BonjourJP , CarrieAL , FerrariS , ClavienH , SlosmanD , TheintzG , et al. Calcium‐enriched foods and bone mass growth in prepubertal girls: a randomized, double‐blind, placebo‐controlled trial. The Journal of Clinical Investigation1997;99(6):1287‐94. [PUBMED: 9077538] ">Bonjour 1997</a>). There is poor evidence to indicate whether calcium supplementation alone reduces the risk of fractures (<a href="./references#CD010899-bbs2-0048" title="BlackRE , WilliamsSM , JonesIE , GouldingA . Children who avoid drinking cow milk have low dietary calcium intakes and poor bone health. The American Journal of Clinical Nutrition2002;76(3):675‐80. [PUBMED: 12198017] ">Black 2002</a>; <a href="./references#CD010899-bbs2-0051" title="BollandMJ , LeungW , TaiV , BastinS , GambleGD , GreyA , et al. Calcium intake and risk of fracture: systematic review. BMJ (Clinical research ed.)2015;351:h4580. [PUBMED: 26420387] ">Bolland 2015</a>; <a href="./references#CD010899-bbs2-0102" title="GouldingA , CannanR , WilliamsSM , GoldEJ , TaylorRW , Lewis‐BarnedNJ . Bone mineral density in girls with forearm fractures. Journal of Bone and Mineral Research1998;13(1):143‐8. [PUBMED: 9443800] ">Goulding 1998</a>; <a href="./references#CD010899-bbs2-0103" title="GouldingA , RockellJE , BlackRE , GrantAM , JonesIE , WilliamsSM . Children who avoid drinking cow's milk are at increased risk for prepubertal bone fractures. Journal of the American Dietetic Association2004;104(2):250‐3. [PUBMED: 14760576] ">Goulding 2004</a>; <a href="./references#CD010899-bbs2-0177" title="PetridouE , KarpathiosT , DessyprisN , SimouE , TrichopoulosD . The role of dairy products and non alcoholic beverages in bone fractures among schoolage children. Scandinavian Journal of Social Medicine1997;25(2):119‐25. [PUBMED: 9232722] ">Petridou 1997</a>; <a href="./references#CD010899-bbs2-0241" title="WinzenbergTM , ShawK , FryerJ , JonesG . Calcium supplementation for improving bone mineral density in children. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005119.pub2] ">Winzenberg 2006</a>). The consumption of adequate dietary calcium and vitamin D can increase bone mineral density in patients with DMD (<a href="./references#CD010899-bbs2-0004" title="BianchiML , MorandiL , AndreucciE , VaiS , FrasunkiewiczJ , CottafavaR . Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteoporosis International2011;22(2):529‐39. [PUBMED: 20458570] ">Bianchi 2011</a>). Evidence that calcium alone has a positive effect on bone health in boys with DMD is limited. </p> </section> <section id="CD010899-sec-0030"> <h4 class="title">Vitamin D</h4> <p>Significantly lower serum 25OHD levels have been highlighted in boys with DMD, especially in those taking corticosteroids (<a href="./references#CD010899-bbs2-0041" title="BianchiM L , MazzantiA , GalbiatiE , SaraifogerS , DubiniA , CornelioF , et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporosis International2003;14(9):761‐7. [PUBMED: 12897980] ">Bianchi 2003</a>; <a href="./references#CD010899-bbs2-0004" title="BianchiML , MorandiL , AndreucciE , VaiS , FrasunkiewiczJ , CottafavaR . Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteoporosis International2011;22(2):529‐39. [PUBMED: 20458570] ">Bianchi 2011</a>). People taking corticosteroids are twice as likely to have low 25OHD levels as those not on corticosteroids (OR 2.36, 95% CI 1.25 to 4.45) (<a href="./references#CD010899-bbs2-0208" title="SkverskyAL , KumarJ , AbramowitzMK , KaskelFJ , MelamedML . Association of glucocorticoid use and low 25‐hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001‐2006. The Journal of Clinical Endocrinology and Metabolism2011;96(12):3838‐45. [PUBMED: 21956424] ">Skversky 2011</a>). <a href="./references#CD010899-bbs2-0073" title="DhawanP , ChristakosS . Novel regulation of 25‐hydroxyvitamin D3 24‐hydroxylase (24(OH)ase) transcription by glucocorticoids: cooperative effects of the glucocorticoid receptor, C/EBP beta, and the Vitamin D receptor in 24(OH)ase transcription. Journal of Cellular Biochemistry2010;110(6):1314‐23. [PUBMED: 20564225] ">Dhawan 2010</a> proposed that corticosteroids may inactivate 25OHD by increasing the activity of the enzyme 24‐hydroxylase. </p> <p>Vitamin D levels collected in boys with DMD aged from 1.5 to 15.5 years prior to starting corticosteroid treatment revealed that 78% had inadequate levels and 15% qualified as deficient (<a href="./references#CD010899-bbs2-0165" title="MunotP , KrishnakumarD , RobbS , DaviesT , MuntoniF , ManzurA . Prevalence of vitamin D deficiency in 157 boys with Duchenne muscular dystrophy. Archives of Disease in Childhood2010;95:A10. ">Munot 2010</a>). In two other studies, 54% to 70% of those with DMD on corticosteroids were vitamin D deficient (<a href="./references#CD010899-bbs2-0152" title="ManzurAY , ScottE , MunotP , VijaykumarK , Muntoni F on behalf of UK NorthStar Clinical Network. UK NorthStar Neuromuscular Clinical Network (NSCN): National audit results in Duchenne muscular dystrophy (DMD) corticosteroid practice, vitamin D status and bone health. Neuromuscular Disorders2010;20(S1):S8. ">Manzur 2010</a>; <a href="./references#CD010899-bbs2-0243" title="WongB , HuSY , KingA , HornP . P4.12 Vitamin D and bone health in Duchenne muscular dystrophy (DMD) patients. Abstracts/Neuromuscular Disorders2010;20(9):662. ">Wong 2010</a>). </p> <p>In a Cochrane Review, the bone mineral density in healthy children taking vitamin D supplements did not change, but bone mineral density did increase in those with low 25OHD levels (<a href="./references#CD010899-bbs2-0242" title="WinzenbergTM , PowellS , ShawKA , JonesG . Vitamin D supplementation for improving bone mineral density in children. Cochrane Database of Systematic Reviews2010, Issue 10. [DOI: 10.1002/14651858.CD006944.pub2] ">Winzenberg 2010</a>). When investigators examined vitamin D levels at the time of a vertebral fracture in boys with DMD, they categorised the mean serum vitamin D levels as insufficient (<a href="./references#CD010899-bbs2-0152" title="ManzurAY , ScottE , MunotP , VijaykumarK , Muntoni F on behalf of UK NorthStar Clinical Network. UK NorthStar Neuromuscular Clinical Network (NSCN): National audit results in Duchenne muscular dystrophy (DMD) corticosteroid practice, vitamin D status and bone health. Neuromuscular Disorders2010;20(S1):S8. ">Manzur 2010</a>). </p> </section> <section id="CD010899-sec-0031"> <h4 class="title">Testosterone</h4> <p>Testosterone is the primary sex hormone for the maturation of sex characteristics in adolescent males. It is also involved in the increase in muscle strength and bone mineral content during puberty (<a href="./references#CD010899-bbs2-0202" title="SeemanE . Clinical review 137: Sexual dimorphism in skeletal size, density, and strength. The Journal of Clinical Endocrinology and Metabolism2001;86(10):4576‐84. [PUBMED: 11600506] ">Seeman 2001</a>; <a href="./references#CD010899-bbs2-0244" title="WoodCL , StraubV , GuglieriM , BushbyK , CheethamT . Short stature and pubertal delay in Duchenne muscular dystrophy. Archives of Disease in Childhood 2015 Jul 3 [Epub ahead of print]. [PUBMED: 26141541] ">Wood 2015</a>). Testosterone is a steroid hormone produced by the testes and the adrenal glands and belongs to a group of male hormones known as androgens. The production of this hormone is regulated by the hypothalamus and pituitary gland. </p> <p>Long‐term corticosteroid treatment in prepubertal boys can slow down growth and delay puberty compared to their healthy peers (<a href="./references#CD010899-bbs2-0244" title="WoodCL , StraubV , GuglieriM , BushbyK , CheethamT . Short stature and pubertal delay in Duchenne muscular dystrophy. Archives of Disease in Childhood 2015 Jul 3 [Epub ahead of print]. [PUBMED: 26141541] ">Wood 2015</a>). All but one of 44 boys with DMD aged 13 years and upwards assessed at Cincinnati Children's Hospital were prepubertal, compared to the 50% of healthy UK boys who are in puberty by 12 years of age (<a href="./references#CD010899-bbs2-0043" title="BianchiML , BiggarD , BushbyK , RogolAD , RutterMM , TsengB . Endocrine aspects of Duchenne muscular dystrophy. Neuromuscular Disorders2011; Vol. 21, issue 4:298‐303. [PUBMED: 21353552] ">Bianchi 2011a</a>; <a href="./references#CD010899-bbs2-0052" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. [PUBMED: 10951436] ">Bonifati 2000</a>). Although not clearly understood, high doses of corticosteroids inhibit or reduce the secretion of gonadotrophin‐releasing hormone by the hypothalamus, which in turn down‐regulates pituitary gonadotrophin production. Corticosteroids may also have a direct effect on the testes to reduce testosterone production. A deficiency in testosterone can delay the onset of puberty (<a href="./references#CD010899-bbs2-0021" title="Al‐HarbiTM , BainbridgeLJ , McQueenMJ , TarnopolskyMA . Hypogonadism is common in men with myopathies. Journal of Clinical Neuromuscular Disease2008;9(4):397‐401. [PUBMED: 18525423] ">Al‐Harbi 2008</a>; <a href="./references#CD010899-bbs2-0080" title="EastellR , ReidDM , CompstonJ , CooperC , FogelmanI , FrancisRM , et al. A UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update. Journal of Internal Medicine1998;244(4):271‐92. [PUBMED: 9797491] ">Eastell 1998</a>; <a href="./references#CD010899-bbs2-0110" title="HampsonG , BhargavaN , CheungJ , VajaS , SeedPT , FogelmanI . Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid‐induced osteoporosis. Metabolism: Clinical and Experimental2002;51(11):1458‐62. [PUBMED: 12404198] ">Hampson 2002</a>; <a href="./references#CD010899-bbs2-0130" title="KamischkeA , KemperDE , CastelMA , LüthkeM , RolfC , BehreHM , et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. The European Respiratory Journal1998;11(1):41‐5. [PUBMED: 9543268] ">Kamischke 1998a</a>; <a href="./references#CD010899-bbs2-0185" title="ReidIR , IbbertsonHK , FranceJT , PybusJ . Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. British Medical Journal (Clinical research ed.)1985;291(6495):574. [PUBMED: 2931151] ">Reid 1985</a>). </p> <p>The absence or delay of puberty has a significant adverse effect on bone health, which is already poor in those with DMD due to corticosteroid treatment, diminishing muscle mass, and reduced mobility (<a href="./references#CD010899-bbs2-0043" title="BianchiML , BiggarD , BushbyK , RogolAD , RutterMM , TsengB . Endocrine aspects of Duchenne muscular dystrophy. Neuromuscular Disorders2011; Vol. 21, issue 4:298‐303. [PUBMED: 21353552] ">Bianchi 2011a</a>; <a href="./references#CD010899-bbs2-0087" title="FairfieldWP , FinkelsteinJS , KlibanskiA , GrinspoonSK . Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. The Journal of Clinical Endocrinology and Metabolism2001;86(5):2020‐6. [PUBMED: 11344201] ">Fairfield 2001</a>; <a href="./references#CD010899-bbs2-0109" title="Cruz Guzmán OdelR , Chávez GarcíaAL , Rodríguez‐CruzM . Muscular dystrophies at different ages: metabolic and endocrine alterations. International Journal of Endocrinology2012;2012:485376. [PUBMED: 22701119] ">Guzman 2012</a>; <a href="./references#CD010899-bbs2-0185" title="ReidIR , IbbertsonHK , FranceJT , PybusJ . Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. British Medical Journal (Clinical research ed.)1985;291(6495):574. [PUBMED: 2931151] ">Reid 1985</a>). Hypogonadism increases the risk of osteoporosis and fractures. Testosterone is an important hormone involved in the development of bone and in the maintenance of bone mineral density in adolescence and adulthood (<a href="./references#CD010899-bbs2-0027" title="AmoryJK , WattsNB , EasleyKA , SuttonPR , AnawaltBD , MatsumotoAM , et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. The Journal of Clinical Endocrinology and Metabolism2004;89(2):503‐10. [PUBMED: 14764753] ">Amory 2004</a>; <a href="./references#CD010899-bbs2-0072" title="DevogelaerJP , DeCoomanS , Nagant de DeuxchaisnesC . Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. Maturitas1992;15(1):17‐23. [PUBMED: 1528128] ">Devogelaer 1992</a>; <a href="./references#CD010899-bbs2-0131" title="KatznelsonL , FinkelsteinJS , SchoenfeldDA , RosenthalDI , AndersonEJ , KlibanskiA . Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. The Journal of Clinical Endocrinology and Metabolism1996;81(12):4358‐65. [PUBMED: 8954042] ">Katznelson 1996</a>; <a href="./references#CD010899-bbs2-0133" title="KennyAM , PrestwoodKM , GrumanCA , MarcelloKM , RaiszLG . Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2001;56(5):M266‐72. [PUBMED: 11320105] ">Kenny 2001</a>; <a href="./references#CD010899-bbs2-0141" title="LederBZ , FinkelsteinJS . Gonadal steroids and the skeleton in men. Clinical aspects. Contemporary Endocrinology: Osteoporosis: Pathophysiology and Clinical Management. Totowa, NJ: Humana Press, 2002:393‐411. ">Leder 2002</a>; <a href="./references#CD010899-bbs2-0221" title="TenoverJS . Effects of testosterone supplementation in the aging male. The Journal of Clinical Endocrinology and Metabolism1992;75(4):1092‐8. [PUBMED: 1400877] ">Tenover 1992</a>). </p> </section> <section id="CD010899-sec-0032"> <h4 class="title">Weight‐bearing exercise</h4> <p>In DMD patients over eight years of age, there is a gradual decline in physical activity due to natural disease progression (<a href="./references#CD010899-bbs2-0156" title="MazzoneE , VascoG , SormaniM P , TorrenteY , BerardinelliA , MessinaS , et al. Functional changes in Duchenne muscular dystrophy: a 12‐month longitudinal cohort study. Neurology2011;77(3):250‐6. [PUBMED: 21734183] ">Mazzone 2011</a>; <a href="./references#CD010899-bbs2-0158" title="McDonaldCM , HenricsonEK , HanJJ , AbreschRT , NicoriciA , ElfringGL , et al. The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle &amp; Nerve2010;41(4):500‐10. [PUBMED: 19941337] ">McDonald 2010</a>). Weight‐bearing exercise, for example, walking, stimulates bone regeneration. Dynamic‐loading activity achieves greater gains in bone tissue than static activity (<a href="./references#CD010899-bbs2-0138" title="LanyonLE , RubinCT . Static vs dynamic loads as an influence on bone remodelling. Journal of Biomechanics1984;17(12):897‐905. [PUBMED: 6520138] ">Lanyon 1984</a>). Muscle weakness hinders dynamic weight‐bearing exercise and has a negative impact on bone development. Disuse of the skeleton as a result of prolonged inactivity degenerates bone tissue further. </p> </section> </section> <section id="CD010899-sec-0033"> <h3 class="title" id="CD010899-sec-0033">How the intervention might work</h3> <p>In children with corticosteroid‐induced osteoporosis, the rate of bone resorption exceeds that of bone formation. The main focus of interventions is either to slow bone resorption or promote bone formation to increase bone mineral density whilst receiving corticosteroid therapy. These interventions can be used alone or in combination to prevent or treat bone loss. </p> <section id="CD010899-sec-0034"> <h4 class="title">Bisphosphonates</h4> <p>Bisphosphonates are drugs that inhibit bone resorption by causing apoptosis of osteoclasts (<a href="./references#CD010899-bbs2-0095" title="FleischH . Bisphosphonates in osteoporosis. European Spine Journal2003;12 Suppl 2:S142‐6. [PUBMED: 13680318] ">Fleisch 2003</a>; <a href="./references#CD010899-bbs2-0180" title="PooleKE , CompstonJE . Bisphosphonates in the treatment of osteoporosis. BMJ2012;344:e3211. [PUBMED: 22619192] ">Poole 2012</a>; <a href="./references#CD010899-bbs2-0192" title="RogersMJ , CrockettJC , CoxonFP , MönkkönenJ . Biochemical and molecular mechanisms of action of bisphosphonates. Bone2011;49(1):34‐41. [PUBMED: 21111853] ">Rogers 2011</a>; <a href="./references#CD010899-bbs2-0195" title="RussellRG , WattsNB , EbetinoFH , RogersMJ . Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International2008;19(6):733‐59. [PUBMED: 18214569] ">Russell 2008</a>). They are inorganic analogues of naturally occurring pyrophosphates, which prevent calcification by binding to hydroxyapatite salt in bone (<a href="./references#CD010899-bbs2-0168" title="NancollasGH , TangR , PhippsRJ , HennemanZ , GuldeS , WuW , et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone2006;38(5):617‐27. [PUBMED: 16046206] ">Nancollas 2006</a>; <a href="./references#CD010899-bbs2-0196" title="RussellRG . Bisphosphonates: the first 40 years. Bone2011;49(1):2‐19. [PUBMED: 21555003] ">Russell 2011</a>; <a href="./references#CD010899-bbs2-0201" title="SebestyenJF , SrivastavaT , AlonUS . Bisphosphonates use in children. Clinical Pediatrics2012;51(11):1011‐24. [PUBMED: 22935217] ">Sebestyen 2012</a>). Bisphosphonates accumulate at bone resorption sites in the skeleton and stop osteoclast‐mediated activity (<a href="./references#CD010899-bbs2-0075" title="DominguezLJ , DiBellaG , BelvedereM , BarbagalloM . Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology2011;12(5):397‐408. [PUBMED: 21695491] ">Dominguez 2011</a>; <a href="./references#CD010899-bbs2-0078" title="DrakeMT , ClarkeBL , KhoslaS . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clinic Proceedings2008;83(9):1032‐45. [PUBMED: 18775204] ">Drake 2008</a>; <a href="./references#CD010899-bbs2-0095" title="FleischH . Bisphosphonates in osteoporosis. European Spine Journal2003;12 Suppl 2:S142‐6. [PUBMED: 13680318] ">Fleisch 2003</a>; <a href="./references#CD010899-bbs2-0120" title="HughesDE , MacDonaldBR , RussellRG , GowenM . Inhibition of osteoclast‐like cell formation by bisphosphonates in long‐term cultures of human bone marrow. The Journal of Clinical Investigation1989;83(6):1930‐5. [PUBMED: 2524504] ">Hughes 1989</a>; <a href="./references#CD010899-bbs2-0121" title="HughesDE , WrightKR , UyHL , SasakiA , YonedaT , RoodmanGD , et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of Bone and Mineral Research1995;10(10):1478‐87. [PUBMED: 8686503] ">Hughes 1995</a>; <a href="./references#CD010899-bbs2-0197" title="SatoM , GrasserW , EndoN , AkinsR , SimmonsH , ThompsonDD , et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. The Journal of Clinical Investigation1991;88(6):2095‐105. [PUBMED: 1661297] ">Sato 1991</a>; <a href="./references#CD010899-bbs2-0201" title="SebestyenJF , SrivastavaT , AlonUS . Bisphosphonates use in children. Clinical Pediatrics2012;51(11):1011‐24. [PUBMED: 22935217] ">Sebestyen 2012</a>; <a href="./references#CD010899-bbs2-0213" title="SomaloL , SantosF . Clinical use of bisphosphonates in children. World Journal of Pediatrics2007;3(4):245‐53. ">Somalo 2007</a>). There are two groups of bisphosphonates: non‐nitrogen‐containing bisphosphonates (etidronate, clodronate, and tiludronate) and nitrogen‐containing bisphosphonates (alendronate, risedronate, ibandronate, pamidronate, and zoledronate). The presence of a nitrogen or amino group in the chemical structure of bisphosphonates increases the potency of the drugs for osteoclastic activity (<a href="./references#CD010899-bbs2-0078" title="DrakeMT , ClarkeBL , KhoslaS . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clinic Proceedings2008;83(9):1032‐45. [PUBMED: 18775204] ">Drake 2008</a>; <a href="./references#CD010899-bbs2-0081" title="EbetinoFH , HoganAM , SunS , TsoumpraMK , DuanX , TriffittJT , et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone2011;49(1):20‐33. [PUBMED: 21497677] ">Ebetino 2011</a>; <a href="./references#CD010899-bbs2-0186" title="ReszkaAA , RodanGA . Nitrogen‐containing bisphosphonate mechanism of action. Mini Reviews in Medicinal Chemistry2004;4(7):711‐9. [PUBMED: 15379639] ">Reszka 2004</a>). These more potent nitrogen‐containing bisphosphonates are often used to treat children with corticosteroid‐induced osteoporosis and osteopenia (<a href="./references#CD010899-bbs2-0024" title="AllingtonN , VivegnisD , GerardP . Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthopaedica Belgica2005;71(1):91‐7. [PUBMED: 15792214] ">Allington 2005</a>; <a href="./references#CD010899-bbs2-0049" title="BlackDM , ReidIR , BoonenS , Bucci‐RechtwegC , CauleyJA , CosmanF , et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON‐Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research2012;27(2):243‐54. [PUBMED: 22161728] ">Black 2012</a>; <a href="./references#CD010899-bbs2-0056" title="BrumsenC , HamdyNA , PapapoulosSE . Long‐term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine1997;76(4):266‐83. [PUBMED: 9279333] ">Brumsen 1997</a>; <a href="./references#CD010899-bbs2-0009" title="HawkerGA , RidoutR , HarrisVA , ChaseCC , FieldingLJ , BiggarWD . Alendronate in the treatment of low bone mass in steroid‐treated boys with Duchennes muscular dystrophy. Archives of Physical Medicine and Rehabilitation2005;86(2):284‐8. [PUBMED: 15706555] ">Hawker 2005</a>; <a href="./references#CD010899-bbs2-0180" title="PooleKE , CompstonJE . Bisphosphonates in the treatment of osteoporosis. BMJ2012;344:e3211. [PUBMED: 22619192] ">Poole 2012</a>; <a href="./references#CD010899-bbs2-0194" title="RudgeS , HailwoodS , HorneA , LucasJ , WuF , CundyT . Effects of once‐weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology2005;44(6):813‐8. [PUBMED: 15695300] ">Rudge 2005</a>; <a href="./references#CD010899-bbs2-0199" title="SchwartzAV , BauerDC , CummingsSR , CauleyJA , EnsrudKE , PalermoL , et al. FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. Journal of Bone and Mineral Research2010;25(5):976‐82. [PUBMED: 20200926] ">Schwartz 2010</a>; <a href="./references#CD010899-bbs2-0207" title="SholasM G , TannB , Gaebler‐SpiraD . Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series. Journal of Pediatric Orthopedics2005;25(3):326‐31. [PUBMED: 15832148] ">Sholas 2005</a>). </p> </section> <section id="CD010899-sec-0035"> <h4 class="title">Calcium</h4> <p>Calcium is essential to enable normal bone growth and development in children and adolescents (<a href="./references#CD010899-bbs2-0096" title="FlynnA . The role of dietary calcium in bone health. Proceedings of the Nutrition Society2003;62(4):851‐8. ">Flynn 2003</a>; <a href="./references#CD010899-bbs2-0173" title="PeacockM . Calcium metabolism in health and disease. Clinical Journal of the American Society of Nephrology2010;5(S1):S23‐30. [PUBMED: 20089499] ">Peacock 2010</a>). When combined with phosphate, calcium has a structural role in bone health as a component of bone matrix hydroxyapatite, which provides compressional strength in bone (<a href="./references#CD010899-bbs2-0054" title="BonjourJP . Calcium and phosphate: a duet of ions playing for bone health. Journal of the American College of Nutrition2011;30(5 Suppl 1):438S‐48S. [PUBMED: 22081690] ">Bonjour 2011</a>; <a href="./references#CD010899-bbs2-0173" title="PeacockM . Calcium metabolism in health and disease. Clinical Journal of the American Society of Nephrology2010;5(S1):S23‐30. [PUBMED: 20089499] ">Peacock 2010</a>). During remodelling, bone turns over calcium. Remodelling activity determines the amount of calcium required to maintain bone health, and this varies throughout life (<a href="./references#CD010899-bbs2-0162" title="MesiasM , SeiquerI , NavarroMP . Calcium nutrition in adolescence. Critical Reviews in Food Science and Nutrition2011;51(3):195‐209. [PUBMED: 21390941] ">Mesias 2011</a>). Calcium requirements are greater during adolescence as growth peaks, and approximately 40% of total skeletal bone mass is acquired (<a href="./references#CD010899-bbs2-0096" title="FlynnA . The role of dietary calcium in bone health. Proceedings of the Nutrition Society2003;62(4):851‐8. ">Flynn 2003</a>; <a href="./references#CD010899-bbs2-0107" title="GreerFR , KrebsNF , American Academy of Pediatrics Committee on Nutrition. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics2006;117(2):578‐85. [PUBMED: 16452385] ">Greer 2006</a>; <a href="./references#CD010899-bbs2-0162" title="MesiasM , SeiquerI , NavarroMP . Calcium nutrition in adolescence. Critical Reviews in Food Science and Nutrition2011;51(3):195‐209. [PUBMED: 21390941] ">Mesias 2011</a>; <a href="./references#CD010899-bbs2-0237" title="WeaverCM , HeaneyRP . Calcium. In: ShilsME , ShikeM , RossAC , CaballeroB , CousinsRJ editor(s). Modern Nutrition in Health and Disease. 10th Edition. Baltimore, MD: Lippincott Williams &amp; Wilkins, 2006:194–210. ">Weaver 2006</a>). Calcium deficiency can contribute to the development of osteoporosis. Not only is there inadequate calcium for bone mineralisation, but bone calcium stores are deleted to maintain blood calcium levels. Reduced blood calcium levels triggers parathyroid hormone (PTH) release (<a href="./references#CD010899-bbs2-0173" title="PeacockM . Calcium metabolism in health and disease. Clinical Journal of the American Society of Nephrology2010;5(S1):S23‐30. [PUBMED: 20089499] ">Peacock 2010</a>). PTH stimulates osteoclasts and bone resorption. High blood calcium levels result in calcitonin release, which inhibits osteoclast activity, promoting bone formation and storage of excess calcium in the bone matrix. </p> <p>The relationship between calcium intake and bone mass is complicated in DMD patients because corticosteroid treatment induces bone resorption, transferring calcium from bone to blood. High blood calcium levels prevent further intestinal calcium absorption to build bone. However, adequate calcium intake could slow bone resorption and contribute to improving bone health in boys and adolescents with DMD (<a href="./references#CD010899-bbs2-0004" title="BianchiML , MorandiL , AndreucciE , VaiS , FrasunkiewiczJ , CottafavaR . Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteoporosis International2011;22(2):529‐39. [PUBMED: 20458570] ">Bianchi 2011</a>; <a href="./references#CD010899-bbs2-0183" title="QuinlivanR , ShawN , BushbyK . 170th ENMC International Workshop: bone protection for corticosteroid treated Duchenne muscular dystrophy. 27‐29 November 2009, Naarden, The Netherlands. Neuromuscular disorders2010;20(11):761‐9. ">Quinlivan 2010</a>). Many intervention studies in DMD patients have advised a daily calcium supplement of 750 mg (<a href="./references#CD010899-bbs2-0009" title="HawkerGA , RidoutR , HarrisVA , ChaseCC , FieldingLJ , BiggarWD . Alendronate in the treatment of low bone mass in steroid‐treated boys with Duchennes muscular dystrophy. Archives of Physical Medicine and Rehabilitation2005;86(2):284‐8. [PUBMED: 15706555] ">Hawker 2005</a>; <a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>). </p> </section> <section id="CD010899-sec-0036"> <h4 class="title">Vitamin D</h4> <p>Vitamin D is vital for intestinal calcium absorption (<a href="./references#CD010899-bbs2-0097" title="FrolikCA , DelucaHF . 1,25‐dihydroxycholecalciferol: the metabolite of vitamin D responsible for increased intestinal calcium transport. Archives of Biochemistry and Biophysics1971;147(1):143‐7. [PUBMED: 4329860] ">Frolik 1971</a>; <a href="./references#CD010899-bbs2-0238" title="WeiMY , GiovannucciEL . Vitamin D and multiple health outcomes in the Harvard cohorts. Molecular Nutrition &amp; Food Research2010;54(8):1114‐26. [PUBMED: 20486209] ">Wei 2010</a>). It may also have its own protective effect on bone (<a href="./references#CD010899-bbs2-0037" title="BartoszewskaM , KambojM , PatelDR . Vitamin D, muscle function, and exercise performance. Pediatric Clinics of North America2010;57(3):849‐61. [PUBMED: 20538161] ">Bartoszewska 2010</a>; <a href="./references#CD010899-bbs2-0176" title="PepponeLJ , HeblS , PurnellJQ , ReidME , RosierRN , MustianKM , et al. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporosis International2010;21(7):1133‐49. [PUBMED: 19960185] ">Peppone 2010</a>). Vitamin D₂ (ergocalciferol) is largely man‐made and present in supplemented food. The skin synthesises vitamin Dɜ (cholecalciferol) after exposure to sunlight, and it is also available in the diet (<a href="./references#CD010899-bbs2-0163" title="MisraM , PacaudD , PetrykA , Collett‐SolbergPF , KappyM . Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics2008;122(2):398‐417. [PUBMED: 18676559] ">Misra 2008</a>). The liver metabolises vitamin D into calcifediol (25‐dihydroxyvitamin Dɜ (25OHD)), which the kidneys convert to the active calcitriol (1,25‐dihydroxyvitamin Dɜ) (<a href="./references#CD010899-bbs2-0176" title="PepponeLJ , HeblS , PurnellJQ , ReidME , RosierRN , MustianKM , et al. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporosis International2010;21(7):1133‐49. [PUBMED: 19960185] ">Peppone 2010</a>). Vitamin D deficiency can cause rickets in children and osteomalacia in adults from poor bone mineralisation (<a href="./references#CD010899-bbs2-0115" title="HolickMF . Vitamin D deficiency. The New England Journal of Medicine2007;357(3):266‐81. [PUBMED: 17634462] ">Holick 2007</a>; <a href="./references#CD010899-bbs2-0175" title="PelaI . How much vitamin D for children?. Clinical Cases in Mineral and Bone Metabolism2012;9(2):112‐7. [PUBMED: 23087722] ">Pela 2012</a>; <a href="./references#CD010899-bbs2-0163" title="MisraM , PacaudD , PetrykA , Collett‐SolbergPF , KappyM . Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics2008;122(2):398‐417. [PUBMED: 18676559] ">Misra 2008</a>; <a href="./references#CD010899-bbs2-0230" title="WagnerCL , GreerFR , American Academy of Pediatrics Section onBreastfeeding , American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics2008;122(5):1142‐52. [PUBMED: 18977996] ">Wagner 2008</a>; <a href="./references#CD010899-bbs2-0234" title="WardLM , GabouryI , LadhaniM , ZlotkinS . Vitamin D‐deficiency rickets among children in Canada. CMAJ Canadian Medical Association Journal2007;177(2):161‐6. [PUBMED: 17600035] ">Ward 2007a</a>). To a lesser extent, vitamin D deficiency contributes to bone resorption and osteoporosis (<a href="./references#CD010899-bbs2-0129" title="JoyceNC , HacheLP , ClemensPR . Bone health and associated metabolic complications in neuromuscular diseases. Physical Medicine and Rehabilitation Clinics of North America2012;23(4):773‐99. [PUBMED: 23137737] ">Joyce 2012</a>; <a href="./references#CD010899-bbs2-0145" title="LipsP , HoskingD , LippunerK , NorquistJM , WehrenL , MaaloufG , et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. Journal of Internal Medicine2006;260(3):245‐54. [PUBMED: 16918822] ">Lips 2006</a>). Many children and young adults in the UK have vitamin D insufficiency from increased use of sunscreens and reduced outdoor activities (<a href="./references#CD010899-bbs2-0045" title="BiggarWD , BachrachLK , HendersonRC , KalkwarfH , PlotkinH , WongBL . Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscular Disorders2005; Vol. 15, issue 1:80‐5. [PUBMED: 15639125] ">Biggar 2005</a>; <a href="./references#CD010899-bbs2-0069" title="DaviesJH , ReedJM , BlakeE , PriesemannM , JacksonAA , ClarkeNM . Epidemiology of vitamin D deficiency in children presenting to a pediatric orthopaedic service in the UK. Journal of Pediatric Orthopedics2011;31(7):798‐802. [PUBMED: 21926880] ">Davies 2011</a>; <a href="./references#CD010899-bbs2-0147" title="LipsP . Interaction between vitamin D and calcium. Scandinavian Journal of Clinical &amp; Laboratory Investigation. Supplementum2012;243:60‐4. [PUBMED: 22536764] ">Lips 2012</a>; <a href="./references#CD010899-bbs2-0163" title="MisraM , PacaudD , PetrykA , Collett‐SolbergPF , KappyM . Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics2008;122(2):398‐417. [PUBMED: 18676559] ">Misra 2008</a>; <a href="./references#CD010899-bbs2-0175" title="PelaI . How much vitamin D for children?. Clinical Cases in Mineral and Bone Metabolism2012;9(2):112‐7. [PUBMED: 23087722] ">Pela 2012</a>). Its prevalence, especially in non‐white families, is underappreciated (<a href="./references#CD010899-bbs2-0020" title="AhmedSF , FraneyC , McDevittH , SomervilleL , ButlerS , GallowayP , et al. Recent trends and clinical features of childhood vitamin D deficiency presenting to a children's hospital in Glasgow. Archives of Disease in Childhood2011;96(7):694‐6. [PUBMED: 20584848] ">Ahmed 2011</a>; <a href="./references#CD010899-bbs2-0132" title="KehlerL , VermaS , KroneR , RoperE . Vitamin D deficiency in children presenting to the emergency department: a growing concern. Vitamin D deficiency in Birmingham's children: presentation to the emergency department. Emergency Medicine Journal2013;30(9):717‐9. [PUBMED: 22962047] ">Kehler 2013</a>; <a href="./references#CD010899-bbs2-0146" title="LipsP . Worldwide status of vitamin D nutrition. The Journal of Steroid Biochemistry and Molecular Biology2010;121(1‐2):297‐300. [PUBMED: 20197091] ">Lips 2010</a>; <a href="./references#CD010899-bbs2-0206" title="ShawN . Vitamin D and bone health in children. BMJ (Clinical research ed.)2011; Vol. 342:d192. [PUBMED: 21266419] ">Shaw 2011</a>; <a href="./references#CD010899-bbs2-0246" title="ZipitisCS , MarkidesGA , SwannIL . Vitamin D deficiency: prevention or treatment?. Archives of Disease in Childhood2006;91(12):1011‐4. [PUBMED: 16945992] ">Zipitis 2006</a>). </p> <p>Calcitriol slows bone resorption and enhances bone mineralisation because it aids calcium absorption. Calcitriol influences the genes that control neuromuscular cell proliferation, differentiation, and apoptosis (<a href="./references#CD010899-bbs2-0036" title="BanerjeeP , ChatterjeeM . Antiproliferative role of vitamin D and its analogs ‐ a brief overview. Molecular and Cellular Biochemistry2003;253(1‐2):247‐54. [PUBMED: 14619976] ">Banerjee 2003</a>; <a href="./references#CD010899-bbs2-0061" title="CarlbergC . Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results in Cancer Research2003;164:29‐42. [PUBMED: 12899512] ">Carlberg 2003</a>; <a href="./references#CD010899-bbs2-0098" title="GarciaLA , KingKK , FerriniMG , NorrisKC , ArtazaJN . 1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology2011;152(8):2976‐86. [PUBMED: 21673099] ">Garcia 2011</a>). There is little evidence that increasing vitamin D intake alone reduces the risk of fractures (<a href="./references#CD010899-bbs2-0047" title="Bischoff‐FerrariHA , WillettWC , WongJB , GiovannucciE , DietrichT , Dawson‐HughesB . Fracture prevention with vitamin D supplementation: a meta‐analysis of randomized controlled trials. JAMA2005;293(18):2257‐64. [PUBMED: 15886381] ">Bischoff‐Ferrari 2005</a>; <a href="./references#CD010899-bbs2-0074" title="DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ2010;340:b5463. [PUBMED: 20068257] ">DIPART 2010</a>; <a href="./references#CD010899-bbs2-0148" title="LookerAC , MussolinoME . Serum 25‐hydroxyvitamin D and hip fracture risk in older U.S. white adults. Journal of Bone and Mineral Research2008;23(1):143‐50. [PUBMED: 17907920] ">Looker 2008</a>). </p> </section> <section id="CD010899-sec-0037"> <h4 class="title">Testosterone</h4> <p>Testosterone therapy increases trabecular bone density (<a href="./references#CD010899-bbs2-0131" title="KatznelsonL , FinkelsteinJS , SchoenfeldDA , RosenthalDI , AndersonEJ , KlibanskiA . Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. The Journal of Clinical Endocrinology and Metabolism1996;81(12):4358‐65. [PUBMED: 8954042] ">Katznelson 1996</a>). Testosterone is used to reverse delayed puberty, reduced growth, and osteoporosis exacerbated by corticosteroid use in DMD (<a href="./references#CD010899-bbs2-0043" title="BianchiML , BiggarD , BushbyK , RogolAD , RutterMM , TsengB . Endocrine aspects of Duchenne muscular dystrophy. Neuromuscular Disorders2011; Vol. 21, issue 4:298‐303. [PUBMED: 21353552] ">Bianchi 2011a</a>). </p> <p>Testosterone replacement therapy is started in low doses at around 14 years of age and increased over three to four years until adult levels are reached. The expected benefits include an increase in bone density, muscle strength, and energy levels from a pubertal growth spurt. </p> <p>Testosterone supplementation can also increase height and improve quality of life during adolescence and young adulthood from an improved body image (<a href="./references#CD010899-bbs2-0137" title="LandonC , RosenfeldRG . Short stature and pubertal delay in male adolescents with cystic fibrosis. Androgen treatment. American Journal of Diseases of Children (1960)1984;138(4):388‐91. [PUBMED: 6702792] ">Landon 1984</a>; <a href="./references#CD010899-bbs2-0153" title="MasonA , WongSC , McGroganP , AhmedSF . Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Hormone Research in Paediatrics2011;75(1):8‐13. [PUBMED: 20664179] ">Mason 2011</a>). A meta‐analysis of eight RCTs examining the use of testosterone in 365 men found moderate gains in lumbar bone density (<a href="./references#CD010899-bbs2-0222" title="TraczMJ , SiderasK , BoloňaER , HaddadRM , KennedyCC , UragaMV , et al. Testosterone use in men and its effects on bone health. A systematic review and meta‐analysis of randomized placebo‐controlled trials. The Journal of Clinical Endocrinology and Metabolism2006;91(6):2011‐6. [PUBMED: 16720668] ">Tracz 2006</a>). Three of the eight studies included men taking corticosteroids (N = 87). The meta‐analysis concluded that the effect of testosterone was weak with regard to osteoporosis prevention and treatment in men, as no bone fracture data were available. Another review of RCTs for the effects of testosterone on body composition in middle‐aged men found that testosterone improved bone mineral density at the lumbar spine by 3.7% (CI 1.0% to 6.4%) compared to placebo (<a href="./references#CD010899-bbs2-0125" title="IsidoriAM , GiannettaE , GrecoEA , GianfrilliD , BonifacioV , IsidoriA , et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle‐aged men: a meta‐analysis. Clinical Endocrinology2005;63(3):280‐93. [PUBMED: 16117815] ">Isidori 2005</a>). </p> </section> <section id="CD010899-sec-0038"> <h4 class="title">Weight‐bearing exercise</h4> <p>The most evident decline in vertebral bone mineral density in DMD appears to occur with the loss of independent ambulation, regardless of whether or not the patient is taking corticosteroids (<a href="./references#CD010899-bbs2-0005" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. [PUBMED: 15336688] ">Biggar 2004</a>; <a href="./references#CD010899-bbs2-0066" title="CrabtreeNJ , RoperH , McMurchieH , ShawNJ . Regional changes in bone area and bone mineral content in boys with Duchenne muscular dystrophy receiving corticosteroid therapy. The Journal of Pediatrics2010;156(3):450‐5. [PUBMED: 19880140] ">Crabtree 2010</a>; <a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>). A reduction in mechanical loading reduces osteoblast bone formation and promotes osteoclast‐mediated bone resorption (<a href="./references#CD010899-bbs2-0218" title="TakataS , YasuiN . Disuse osteoporosis. The Journal of Medical Investigation2001;48(3‐4):147‐56. [PUBMED: 11694954] ">Takata 2001</a>). A study revealed that bone mineral density at a number of sites including the lumbar spine improved with calcium and exercise in prepubertal and early pubertal boys (<a href="./references#CD010899-bbs2-0038" title="BassSL , NaughtonG , SaxonL , Iuliano‐BurnsS , DalyR , BrigantiEM , et al. Exercise and calcium combined results in a greater osteogenic effect than either factor alone: a blinded randomized placebo‐controlled trial in boys. Journal of Bone and Mineral Research2007;22(3):458‐64. [PUBMED: 17181396] ">Bass 2007</a>; <a href="./references#CD010899-bbs2-0126" title="Iuliano‐BurnsS , SaxonL , NaughtonG , GibbonsK , BassSL . Regional specificity of exercise and calcium during skeletal growth in girls: a randomized controlled trial. Journal of Bone and Mineral Research2003;18(1):156‐62. [PUBMED: 12510818] ">Iuliano‐Burns 2003</a>; <a href="./references#CD010899-bbs2-0215" title="StearSJ , PrenticeA , JonesSC , ColeTJ . Effect of a calcium and exercise intervention on the bone mineral status of 16‐18‐y‐old adolescent girls. The American Journal of Clinical Nutrition2003;77(4):985‐92. [PUBMED: 12663301] ">Stear 2003</a>). The Iowa Bone Development Study found significant longitudinal associations between physical activity that increased the mechanical loading of the skeleton in boys aged five years and bone mineral content of the hip at eight and 11 years of age (<a href="./references#CD010899-bbs2-0128" title="JanzKF , LetuchyEM , Eichenberger GilmoreJM , BurnsTL , TornerJC , WillingMC , et al. Early physical activity provides sustained bone health benefits later in childhood. Medicine &amp; Science in Sports and Exercise2010;42(6):1072‐8. ">Janz 2010</a>). Growing bone adapts to withstand mechanical loading. In boys with DMD, standing programs and prolongation of walking using mechanical walking aids are common components of management (<a href="./references#CD010899-bbs2-0174" title="PedlowK , McDonoughS , LennonS , KerrC , BradburyI . Assisted standing for Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD011550] ">Pedlow 2015</a>), and boys have shown improvement in vertebral bone mineral density and function capacity (<a href="./references#CD010899-bbs2-0001" title="BianchiML , VaiS , MorandiL , BaranelloG , PasanisiB , RubinC . Effects of low‐magnitude high‐frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy. Journal of Bone and Mineral Research2013;28(Suppl 1):Poster No: LB‐SU03. [EMBASE: 71508066] ">Bianchi 2013</a>; <a href="./references#CD010899-bbs2-0214" title="SpencerGEJr , VignosPJJr . Bracing for ambulation in childhood progressive muscular dystrophy. The Journal of Bone &amp; Joint Surgery. American Volume1962;44 A:234‐42. [PUBMED: 14039442] ">Spencer 1962</a>). More recently, high‐frequency, low‐intensity whole‐body vibration appeared to improve bone health in children and adolescents with a disability (<a href="./references#CD010899-bbs2-0155" title="Matute‐LlorenteA , González‐AgüeroA , Gómez‐CabelloA , OlmedillasH , Vicente‐RodríguezG , CasajúsJA . Effect of whole body vibration training on bone mineral density and bone quality in adolescents with Down syndrome: a randomized controlled trial. Osteoporosis International2015;26(10):2449‐59. [PUBMED: 25994905] ">Matute‐Llorente 2015</a>; <a href="./references#CD010899-bbs2-0188" title="ReyesML , HernándezM , HolmgrenLJ , SanhuezaE , EscobarRG . High‐frequency, low‐intensity vibrations increase bone mass and muscle strength in upper limbs, improving autonomy in disabled children. Journal of Bone and Mineral Research2011;26(8):1759‐66. [PUBMED: 21491486] ">Reyes 2011;</a><a href="./references#CD010899-bbs2-0193" title="RuckJ , ChabotG , RauchF . Vibration treatment in cerebral palsy: a randomized controlled pilot study. Journal of Musculoskeletal &amp; Neuronal Interactions2010;10(1):77‐83. [PUBMED: 20190383] ">Ruck 2010</a>), but was inconclusive in people with DMD (<a href="./references#CD010899-bbs2-0014" title="SöderpalmAC , KroksmarkAK , MagnussonP , KarlssonJ , TuliniusM , Swolin‐EideD . Whole body vibration therapy in patients with Duchenne muscular dystrophy ‐ a prospective observational study. Journal of Musculoskeletal &amp; Neuronal Interactions2013;13(1):13‐8. [PUBMED: 23445910] ">Söderpalm 2013</a>). Regular low‐intensity and appropriate exercise strengthens bone tissue, as well as improving the balance of action between opposing muscle groups and balance while standing and moving (<a href="./references#CD010899-bbs2-0059" title="BushbyK , FinkelR , BirnkrantD J , CaseLE , ClemensPR , CripeL , et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology2010;9(2):177‐89. [PUBMED: 19945914] ">Bushby 2010</a>; <a href="./references#CD010899-bbs2-0106" title="GrangeRW , CallJA . Recommendations to define exercise prescription for Duchenne muscular dystrophy. Exercise and Sport Sciences Reviews2007;35(1):12‐7. [PUBMED: 17211188] ">Grange 2007</a>; <a href="./references#CD010899-bbs2-0127" title="JansenM , deGrootIJ , vanAlfenN , GeurtsACh . Physical training in boys with Duchenne muscular dystrophy: the protocol of the No Use is Disuse study. BMC Pediatrics2010;10:55. [PUBMED: 20691042] ">Jansen 2010</a>). These interventions could reduce the risk of fractures in non‐ambulant boys (<a href="./references#CD010899-bbs2-0233" title="WardK , AlsopC , CaultonJ , RubinC , AdamsJ , MughalZ . Low magnitude mechanical loading is osteogenic in children with disabling conditions. Journal of Bone and Mineral Research2004;19(3):360‐9. [PUBMED: 15040823] ">Ward 2004</a>). </p> </section> </section> <section id="CD010899-sec-0039"> <h3 class="title" id="CD010899-sec-0039">Why it is important to do this review</h3> <p>Corticosteroids delay the loss of ambulation and cardiorespiratory failure in patients with DMD. However, boys require treatment for many years, and the risk of vertebral fragility and possibly long‐bone fractures is high. Identifying treatment strategies to prevent and treat osteoporosis and prevent fragility fractures will improve the quality of life for these patients. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010899-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010899-sec-0040"></div> <p>To assess the effects of interventions to delay or treat osteoporosis in children and adults with DMD taking long‐term corticosteroids; to assess the effects of these interventions on the frequency of vertebral fragility fractures and long‐bone fractures, and on quality of life; and to assess adverse events. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010899-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010899-sec-0041"></div> <section id="CD010899-sec-0042"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010899-sec-0043"> <h4 class="title">Types of studies</h4> <p>We searched for all randomised controlled trials (RCTs) and quasi‐RCTs involving treatment or prevention of corticosteroid‐induced osteoporosis and prevention of fragility fractures in patients with DMD who were taking corticosteroids. Quasi‐RCTs employ methods of allocation that are not truly randomised (for example, by alternation or using date of birth or hospital number). </p> </section> <section id="CD010899-sec-0044"> <h4 class="title">Types of participants</h4> <p>We considered for inclusion in the review all children, adolescents, and adults with a diagnosis of DMD, with any pathogenic mutation, deletion, or duplication confirmed by genetic testing or muscle biopsy showing the complete absence of dystrophin. </p> </section> <section id="CD010899-sec-0045"> <h4 class="title">Types of interventions</h4> <p>We considered for inclusion in the review any intervention to prevent or treat corticosteroid‐induced osteoporosis or prevent fragility fractures in patients with DMD compared with placebo, another intervention, or no treatment (no available standard care). </p> <p>The interventions included oral and intravenous bisphosphonates (including both non‐amino and amino groups), vitamin D supplements, calcium supplements, dietary calcium, testosterone, and weight‐bearing activity. </p> <p>We planned to analyse oral and intravenous bisphosphonates separately.</p> </section> <section id="CD010899-sec-0046"> <h4 class="title">Types of outcome measures</h4> <section id="CD010899-sec-0047"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010899-list-0001"> <li> <p>Change in vertebral bone mineral density measured by dual‐energy X‐ray absorptiometry (DXA) and expressed as a Z‐score (which is based on age‐matched results with a correction for body height) between baseline and 24 months of intervention. </p> </li> </ol> </p> <p>The presence of vertebral compression fractures could artificially increase bone mineral density and produce higher Z‐scores in an individual. However, we considered this effect unlikely to influence the outcome of a meta‐analysis. </p> </section> <section id="CD010899-sec-0048"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes measured between baseline and 24 months of intervention.</p> <p> <ol id="CD010899-list-0002"> <li> <p>The number of vertebral fragility fractures, defined as one or a combination of the following: end‐plate deformity with a reduction in the mid‐vertebral height (biconcavity), decrease in the anterior vertebral height (wedging), or reduction in the anterior and posterior vertebral height (compression or crush). Identification of such vertebral fractures was based on visual evaluation with an assessment of grade or severity linked to vertebral height, shape, and appearance (<a href="./references#CD010899-bbs2-0034" title="BaimS , LeonardMB , BianchiML , HansDB , KalkwarfHJ , LangmanCB , et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. Journal of Clinical Densitometry2008;11(1):6‐21. [PUBMED: 18442749] ">Baim 2008</a>), for example, using the Genant visual semi‐quantitative method (<a href="./references#CD010899-bbs2-0099" title="GenantHK , WuCY , vanKuijkC , NevittMC . Vertebral fracture assessment using a semiquantitative technique. Journal of Bone and Mineral Research1993;8(9):1137‐48. [PUBMED: 8237484] ">Genant 1993</a>). Fractures were detected using lateral spinal X‐ray, DXA vertebral fracture assessment (VFA), computed‐tomography (CT) scans, or magnetic resonance imaging (MRI). </p> </li> <li> <p>The number of long‐bone fractures.</p> </li> <li> <p>Change in reported bone pain measured using a standardised pain score (<a href="./references#CD010899-bbs2-0159" title="McGrathPJ , WalcoGA , TurkDC , DworkinRH , BrownMT , DavidsonK , et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. The Journal of Pain2008;9(9):771‐83. [PUBMED: 18562251] ">McGrath 2008</a>), such as the visual analogue scale (VAS) (<a href="./references#CD010899-bbs2-0200" title="ScottJ , HuskissonEC . Vertical or horizontal visual analogue scales. Annals of the Rheumatic Diseases1979;38(6):560. [PUBMED: 317239] ">Scott 1979</a>; <a href="./references#CD010899-bbs2-0245" title="ZebrackiK , DrotarD . Pain and activity limitations in children with Duchenne or Becker muscular dystrophy. Developmental Medicine &amp; Child Neurology2008;50(7):546‐52. [PUBMED: 18611207] ">Zebracki 2008</a>). </p> </li> <li> <p>Change in quality of life, measured using a validated rating scale, for example, the Pediatric Quality of Life Inventory (PedsQL) (<a href="./references#CD010899-bbs2-0226" title="VarniJW , SeidM , KurtinPS . PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Medical Care2001;39(8):800‐12. [PUBMED: 11468499] ">Varni 2001</a>), Neuromuscular Module and Generic Core Scales (<a href="./references#CD010899-bbs2-0070" title="DavisSE , HynanLS , LimbersCA , AndersenCM , GreeneMC , VarniJW , et al. The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales. Journal of Clinical Neuromuscular Disease2010;11(3):97‐109. [PUBMED: 20215981] ">Davis 2010</a>). </p> </li> <li> <p>Any adverse events; adverse events that led to the withdrawal of treatment; serious adverse events that are fatal, life‐threatening, or led to prolonged hospitalisation; and specific adverse events, such as jaw osteonecrosis and atypical femur fractures. </p> </li> </ol> </p> </section> </section> </section> <section id="CD010899-sec-0049"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010899-sec-0050"> <h4 class="title">Electronic searches</h4> <p>On 12 September 2016, we searched the following databases to identify potentially eligible trials: </p> <p> <ul id="CD010899-list-0003"> <li> <p>the Cochrane Neuromuscular Specialised Register;</p> </li> <li> <p>CENTRAL (the Cochrane Central Register of Controlled Trials) in the Cochrane Register of Studies Online; </p> </li> <li> <p>MEDLINE OvidSP (1966 to September 2016);</p> </li> <li> <p>Embase OvidSP (1980 to September 2016);</p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature) Plus (1982 to September 2016); and </p> </li> <li> <p>Web of Science Core Collection (Proceedings paper or Meeting abstract) (2001 to September 2016). </p> </li> </ul> </p> <p>We did not limit our search by language or publication status.</p> <p>The detailed search strategies are in the appendices.</p> <p> <ul id="CD010899-list-0004"> <li> <p>Cochrane Neuromuscular Specialised Register (<a href="./appendices#CD010899-sec-0086">Appendix 1</a>) </p> </li> <li> <p>CENTRAL (<a href="./appendices#CD010899-sec-0087">Appendix 2</a>) </p> </li> <li> <p>MEDLINE (<a href="./appendices#CD010899-sec-0088">Appendix 3</a>) </p> </li> <li> <p>Embase (<a href="./appendices#CD010899-sec-0089">Appendix 4</a>) </p> </li> <li> <p>CINAHL Plus (<a href="./appendices#CD010899-sec-0090">Appendix 5</a>) </p> </li> <li> <p>WOS (<a href="./appendices#CD010899-sec-0091">Appendix 6</a>) </p> </li> </ul> </p> </section> <section id="CD010899-sec-0051"> <h4 class="title">Searching other resources</h4> <p>In addition, we searched the following registries to identify unpublished data, unpublished studies, and ongoing trials: </p> <p> <ul id="CD010899-list-0005"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 11 October 2011); </p> </li> <li> <p>the World Health Organization International Clinical Trials Registry Platform (ICTRP, <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>; searched 11 October 2011); and </p> </li> <li> <p>the ISRCTN registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>; searched 11 October 2011). </p> </li> </ul> </p> <p>We presented detailed search strategies in the appendices.</p> <p> <ul id="CD010899-list-0006"> <li> <p>ClinicalTrials.gov (<a href="./appendices#CD010899-sec-0092">Appendix 7</a>) </p> </li> <li> <p>ICTRP (<a href="./appendices#CD010899-sec-0093">Appendix 8</a>) </p> </li> <li> <p>ISRCTN registry (<a href="./appendices#CD010899-sec-0094">Appendix 9</a>) </p> </li> </ul> </p> </section> </section> <section id="CD010899-sec-0052"> <h3 class="title" id="CD010899-sec-0052">Data collection and analysis</h3> <section id="CD010899-sec-0053"> <h4 class="title">Selection of studies</h4> <p>Two review authors (JMB and MS) independently reviewed titles and abstracts from the electronic search results and selected papers for full‐text review according to the inclusion criteria. We obtained the full text of all potentially relevant studies for further assessment and selected studies that met the inclusion criteria. We would have resolved disagreements by discussion, but there were no disagreements. We agreed by discussion to contact five study authors to obtain further information for clarification on published work, unpublished studies, and work in progress. </p> <p>We collated multiple reports of the same study under the same study ID. We completed a PRISMA flow diagram, 'Characteristics of excluded studies' tables, and 'Characteristics of ongoing studies' tables to detail the selection process. </p> <p>A lack of randomised trials, other than two abstracts, meant that the two review authors (JMB and MS) were unable to extract data. </p> </section> <section id="CD010899-sec-0054"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JMB and MS) independently assessed the risk of bias in the included studies, and a third (BB) verified the assessments. We used the domain‐based evaluation described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010899-bbs2-0113" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). The domains included the following: </p> <p> <ol id="CD010899-list-0007"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessors;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective reporting; and</p> </li> <li> <p>other bias.</p> </li> </ol> </p> <p>For each domain, we graded the risk of bias as high, low, or unclear (<a href="./references#CD010899-bbs2-0113" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We contacted the trial's corresponding authors for clarification of insufficient detail in study reports. We resolved disagreements through discussion with the other review authors, and we assigned studies to the following categories. </p> <p> <ul id="CD010899-list-0008"> <li> <p>Low risk of bias: all domains at low risk of bias.</p> </li> <li> <p>High risk of bias: two or more domains at high risk of bias.</p> </li> <li> <p>Unclear risk of bias: one or more domains at unclear risk of bias.</p> </li> </ul> </p> <p>We constructed a 'Risk of bias' table using RevMan to present the results. When considering treatment effects, we planned to take into account the risk of bias in the studies that contributed to the outcome. </p> <p>We would have used the 'Risk of bias' assessments to perform sensitivity analyses, if sufficient data had been available. </p> <p>Information on risk of bias related to unpublished data or correspondence with a trialist was noted in the 'Risk of bias' table. </p> <section id="CD010899-sec-0055"> <h5 class="title">Assesment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD010899-bbs2-0247" title="BellJM , BlackwoodB , ShieldsMD , WattersJ , HamiltonA , BeringerT , et al. Interventions to prevent steroid‐induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD010899] ">Bell 2014</a>). We would have reported any deviations from protocol in <a href="#CD010899-sec-0112">Differences between protocol and review</a>. </p> <p><a href="./appendices#CD010899-sec-0095">Appendix 10</a> details methods described in the protocol to be followed if data become available for analysis in future. </p> </section> </section> <section id="CD010899-sec-0056"> <h4 class="title">Data synthesis</h4> <p>In the absence of meta‐analysis or full‐text trial reports, we presented the limited data available narratively, in the <a href="./full#CD010899-sec-0057">Results</a> section. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010899-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010899-sec-0057"></div> <section id="CD010899-sec-0058"> <h3 class="title">Description of studies</h3> <section id="CD010899-sec-0059"> <h4 class="title">Results of the search</h4> <p>The total number of potentially relevant references retrieved from each database was 645: 58 from the Cochrane Neuromuscular Specialised Register, 78 from the Cochrane Central Register of Controlled Trials (CENTRAL), 303 from MEDLINE, 159 from Embase, 22 from CINAHL (Cumulative Index to Nursing and Allied Health Literature) Plus, and 25 from Web of Science ISI Proceedings. The number of references from database searches after deduplication was 506. </p> <p>We identified 30 additional references from other sources: four from the US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), seven from the ISRCTN registry, 17 from ICTRP, one published study from correspondence with a co‐author (AH), and one unpublished study from correspondence with an author of related studies. The number of studies from these sources after deduplication was 26. </p> <p>The number of references selected for further review based on their titles and abstracts was 18. Of these, only two met the inclusion criteria for the review, but only conference abstracts were available. We requested unpublished data from the authors of both studies; one responded with further information, and the second did not respond. We categorised two further studies as <a href="./references#CD010899-bbs1-0003" title="">Ongoing studies</a>. </p> <p>We illustrated the overall study selection process in a flow diagram (<a href="#CD010899-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010899-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="A flow diagram illustrating the study selection process." data-id="CD010899-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/image_n/nCD010899-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>A flow diagram illustrating the study selection process.</p> </div> </div> </div> </section> <section id="CD010899-sec-0060"> <h4 class="title">Included studies</h4> <p>We found two randomised clinical trials that appeared relevant for inclusion in this review (see <a href="./references#CD010899-sec-0114" title="">Characteristics of included studies</a>). </p> <p><a href="./references#CD010899-bbs2-0002" title="EudraCT2009‐017649‐67 . Bone health in Duchenne muscular dystrophy ‐ a case controlled study of risedronate use. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐017649‐67 (accessed 18 December 2015). McSweeneyN , McKennaM , Van DerKampS , KilbaneM , McDonnellC , MurphyN , et al. Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial. Hormone Research in Paediatrics2014;82(Suppl 1):196‐7. [EMBASE: 71653083] ">McSweeney 2014</a> assessed the effects of bisphosphonate therapy (risedronate 1 mg/kg, maximum 35 mg) combined with calcium (500 mg/day) and vitamin D (10 mg/day) compared to calcium and vitamin D alone in a randomised controlled trial (RCT) involving 13 boys with Duchenne muscular dystrophy (DMD). The median age of participants was 8.5 years (range 5.4 to 15.5 years); nine boys were ambulant and on corticosteroid therapy. The abstract did not provide information on funding sources. </p> <p><a href="./references#CD010899-bbs2-0001" title="BianchiML , VaiS , MorandiL , BaranelloG , PasanisiB , RubinC . Effects of low‐magnitude high‐frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy. Journal of Bone and Mineral Research2013;28(Suppl 1):Poster No: LB‐SU03. [EMBASE: 71508066] ">Bianchi 2013</a> investigated weight‐bearing activity (low‐magnitude high‐frequency vibration) compared to the effects of a placebo device on bone mineral density in 21 ambulant boys who had received corticosteroids for at least six months. The trial had a prospective, double‐blind, randomised, placebo‐controlled design. The abstract did not provide information on funding sources. </p> <p>Both studies were reported in conference abstracts, but there was insufficient information available to collect outcome data or assess risk of bias. We contacted both primary authors for further information: <a href="./references#CD010899-bbs2-0001" title="BianchiML , VaiS , MorandiL , BaranelloG , PasanisiB , RubinC . Effects of low‐magnitude high‐frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy. Journal of Bone and Mineral Research2013;28(Suppl 1):Poster No: LB‐SU03. [EMBASE: 71508066] ">Bianchi 2013</a> had no further information to offer until publication, and we received no response from <a href="./references#CD010899-bbs2-0002" title="EudraCT2009‐017649‐67 . Bone health in Duchenne muscular dystrophy ‐ a case controlled study of risedronate use. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐017649‐67 (accessed 18 December 2015). McSweeneyN , McKennaM , Van DerKampS , KilbaneM , McDonnellC , MurphyN , et al. Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial. Hormone Research in Paediatrics2014;82(Suppl 1):196‐7. [EMBASE: 71653083] ">McSweeney 2014</a>. We do not have information on when we can expect full publication of the results. </p> </section> <section id="CD010899-sec-0061"> <h4 class="title">Excluded studies</h4> <p>We excluded 14 studies that did not meet the inclusion criteria for this review (see <a href="./references#CD010899-sec-0115" title="">Characteristics of excluded studies</a>). The reasons for rejection were that the studies did not include patients with DMD in the study population (<a href="./references#CD010899-bbs2-0003" title="AdachiJD , SaagKG , DelmasPD , LibermanUA , EmkeyRD , SeemanE , et al. Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial. Arthritis &amp; Rheumatism2001;44(1):202‐11. [PUBMED: 11212161] ">Adachi 2001</a>; <a href="./references#CD010899-bbs2-0007" title="CohranV , CassedyA , HawkinsA , BeanJ , HeubiJ . Oral risedronate sodium improves bone mineral density in non‐ambulatory patients: a randomized, double‐blind, placebo controlled trial. Journal of Pediatric Rehabilitation Medicine2013;6(2):85‐93. [PUBMED: 23803341] ">Cohran 2013</a>), were not randomised (<a href="./references#CD010899-bbs2-0004" title="BianchiML , MorandiL , AndreucciE , VaiS , FrasunkiewiczJ , CottafavaR . Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteoporosis International2011;22(2):529‐39. [PUBMED: 20458570] ">Bianchi 2011</a>; <a href="./references#CD010899-bbs2-0005" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. [PUBMED: 15336688] ">Biggar 2004</a>; <a href="./references#CD010899-bbs2-0006" title="CohranVC , GriffithsM , HeubiJE . Bone mineral density in children exposed to chronic glucocorticoid therapy. Clinical Pediatrics2008;47(5):469‐75. [PUBMED: 18378941] ">Cohran 2008</a>, <a href="./references#CD010899-bbs2-0009" title="HawkerGA , RidoutR , HarrisVA , ChaseCC , FieldingLJ , BiggarWD . Alendronate in the treatment of low bone mass in steroid‐treated boys with Duchennes muscular dystrophy. Archives of Physical Medicine and Rehabilitation2005;86(2):284‐8. [PUBMED: 15706555] ">Hawker 2005</a>; <a href="./references#CD010899-bbs2-0010" title="HoustonC , MathewsK , Shibli‐RahhalA . Bone density and alendronate effects in Duchenne muscular dystrophy patients. Muscle &amp; Nerve2014;49(4):506‐11. [PUBMED: 23835890] ">Houston 2014</a>; <a href="./references#CD010899-bbs2-0011" title="MayoAL , CravenBC , McAdamLC , BiggarWD . Bone health in boys with Duchenne muscular dystrophy on long‐term daily deflazacort therapy. Neuromuscular Disorders2012;22(12):1040‐5. [PUBMED: 22824639] ">Mayo 2012</a>; <a href="./references#CD010899-bbs2-0015" title="SrinivasanR , RawlingsD , WoodCL , CheethamT , MorenoAC , MayhewA , et al. Prophylactic oral bisphosphonate therapy in Duchenne muscular dystrophy. Muscle &amp; Nerve2016;54(1):79‐85. [DOI: 10.1002/mus.24991; PUBMED: 26599341] ">Srinivasan 2016</a>; <a href="./references#CD010899-bbs2-0012" title="SbrocchiAM , RauchF , JacobP , McCormickA , McMillanHJ , MatzingerMA , et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporosis International2012;23(11):2703‐11. [PUBMED: 22297733] ">Sbrocchi 2012</a>; <a href="./references#CD010899-bbs2-0014" title="SöderpalmAC , KroksmarkAK , MagnussonP , KarlssonJ , TuliniusM , Swolin‐EideD . Whole body vibration therapy in patients with Duchenne muscular dystrophy ‐ a prospective observational study. Journal of Musculoskeletal &amp; Neuronal Interactions2013;13(1):13‐8. [PUBMED: 23445910] ">Söderpalm 2013</a>), or did not assess the effects of the intervention on bone health (<a href="./references#CD010899-bbs2-0008" title="DubowitzV , HydeSA , ScottOM , GoddardC . Controlled trial of exercise in Duchenne muscular dystrophy. In: SerratriceG editor(s). Neuromuscular diseases. New York: Raven Press, 1984:571‐5. ">Dubowitz 1984</a>; <a href="./references#CD010899-bbs2-0013" title="ScottOM , HydeSA , GoddardC , JonesR , DubowitzV . Effect of exercise in Duchenne muscular dystrophy. Physiotherapy1981;67(6):174‐6. [PUBMED: 7029578] ">Scott 1981</a>; <a href="./references#CD010899-bbs2-0016" title="YılmazO , KaradumanA , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. European Journal of Neurology2004;11(8):541‐4. [PUBMED: 15272899] ">Yilmaz 2004</a>). </p> <section id="CD010899-sec-0062"> <h5 class="title">Ongoing studies</h5> <p>We found two ongoing clinical studies (see <a href="./references#CD010899-sec-0116" title="">Characteristics of ongoing studies</a>). The first was a RCT to assess the effect of a novel whole‐body vibration therapy on bone health as well as muscle strength (<a href="./references#CD010899-bbs2-0018" title="NCT01954940 . Whole body vibration therapy in boys with Duchenne muscular dystrophy [The effect of whole body vibration therapy upon muscle strength &amp; function in ambulatory boys with Duchenne muscular dystrophy]. www.clinicaltrials.gov/ct2/show/NCT01954940 (accessed 18 December 2015). ">NCT01954940</a>). This trial was registered on 13 September 2013, with an estimated recruitment end date in March 2015. The study is still recruiting participants (last verified 26 July 2016). The second was a RCT of zoledronic acid (Aclasta) versus vitamin D plus calcium in children and adolescents with DMD, to assess change in lumbar spine bone density over 12 months (<a href="./references#CD010899-bbs2-0017" title="ACTRN12610000507088 . Clinical trial of zoledronic acid in children and adolescents with Duchenne muscular dystrophy [Open label, randomized clinical trial of zoledronic acid (Aclasta) versus vitamin D plus calcium in children and adolescents with Duchenne muscular dystrophy, to assess change in lumbar spine bone density over 12 months]. www.anzctr.org.au/ACTRN12610000507088.aspx (first received 15 June 2010). ">ACTRN12610000507088</a>). The trial was registered on 18 June 2010, and the anticipated date of the enrollment of the last participant is 31 December 2016. </p> </section> </section> </section> <section id="CD010899-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD010899-sec-0114" title="">Characteristics of included studies</a> and <a href="#CD010899-fig-0001">Figure 1</a> and <a href="#CD010899-fig-0002">Figure 2</a> for 'Risk of bias' assessments. As information was only available from abstracts, we were limited in our ability to fully assess risk of bias. We assessed random sequence generation as low risk for both studies (<a href="./references#CD010899-bbs2-0001" title="BianchiML , VaiS , MorandiL , BaranelloG , PasanisiB , RubinC . Effects of low‐magnitude high‐frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy. Journal of Bone and Mineral Research2013;28(Suppl 1):Poster No: LB‐SU03. [EMBASE: 71508066] ">Bianchi 2013</a>; <a href="./references#CD010899-bbs2-0002" title="EudraCT2009‐017649‐67 . Bone health in Duchenne muscular dystrophy ‐ a case controlled study of risedronate use. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐017649‐67 (accessed 18 December 2015). McSweeneyN , McKennaM , Van DerKampS , KilbaneM , McDonnellC , MurphyN , et al. Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial. Hormone Research in Paediatrics2014;82(Suppl 1):196‐7. [EMBASE: 71653083] ">McSweeney 2014</a>) and blinding as low risk for (<a href="./references#CD010899-bbs2-0001" title="BianchiML , VaiS , MorandiL , BaranelloG , PasanisiB , RubinC . Effects of low‐magnitude high‐frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy. Journal of Bone and Mineral Research2013;28(Suppl 1):Poster No: LB‐SU03. [EMBASE: 71508066] ">Bianchi 2013</a>). We assessed all other domains as unclear. </p> <div class="figure" id="CD010899-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Green = low risk of bias; yellow = unclear risk of bias; red (not shown) = high risk of bias." data-id="CD010899-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/image_n/nCD010899-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Green = low risk of bias; yellow = unclear risk of bias; red (not shown) = high risk of bias. </p> </div> </div> </div> </section> <section id="CD010899-sec-0064"> <h3 class="title" id="CD010899-sec-0064">Effects of interventions</h3> <section id="CD010899-sec-0065"> <h4 class="title">Risedronate, calcium, and vitamin D versus calcium and vitamin D alone</h4> <p>Studied in <a href="./references#CD010899-bbs2-0002" title="EudraCT2009‐017649‐67 . Bone health in Duchenne muscular dystrophy ‐ a case controlled study of risedronate use. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐017649‐67 (accessed 18 December 2015). McSweeneyN , McKennaM , Van DerKampS , KilbaneM , McDonnellC , MurphyN , et al. Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial. Hormone Research in Paediatrics2014;82(Suppl 1):196‐7. [EMBASE: 71653083] ">McSweeney 2014</a> </p> <p><a href="./references#CD010899-bbs2-0002" title="EudraCT2009‐017649‐67 . Bone health in Duchenne muscular dystrophy ‐ a case controlled study of risedronate use. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐017649‐67 (accessed 18 December 2015). McSweeneyN , McKennaM , Van DerKampS , KilbaneM , McDonnellC , MurphyN , et al. Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial. Hormone Research in Paediatrics2014;82(Suppl 1):196‐7. [EMBASE: 71653083] ">McSweeney 2014</a> (N = 13) randomised participants with a spine Z‐score less than ‐1.0 to risedronate plus calcium and vitamin D (N = 6) or to calcium and vitamin D alone (N = 7). At baseline and 12 months, investigators measured the spine and whole body bone mineral density Z‐score in both groups (<a href="#CD010899-tbl-0001">Table 1</a>). The study authors reported a significant improvement in bone mineral density of the spine and whole body at 12 months compared to baseline in the risedronate group. The published abstract reported no information on fractures. Nine participants were ambulant and taking corticosteroid therapy, but it is unclear whether those taking risdronate were ambulant. If current practice was applied, all participants given risdronate would be taking corticosteroids. The abstract did not provide information on adverse events. </p> <div class="table" id="CD010899-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Spine and whole‐body Z‐scores (McSweeney 2014)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Risedronate (plus calcium and vitamin D supplementation)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Control (calcium and vitamin D supplementation alone)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12‐month</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median spine Z‐score (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.75 (‐1.2 to ‐3.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.8 (‐1.7 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.2 (‐4.1 to ‐1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.6 (‐8.4 to ‐0.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median whole‐body Z‐score (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.95 (‐0.5 to 2.7)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (‐1.0 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.2 (‐1.6 to 4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.8 (‐3.1 to 3)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>A median of ‐1.95 is outside the range given, but we were unable to confirm correct figures with the study author. </p> </div> </div> </section> <section id="CD010899-sec-0066"> <h4 class="title">Weight‐bearing activity (low‐magnitude high‐frequency vibration) versus placebo device</h4> <p>Studied in <a href="./references#CD010899-bbs2-0001" title="BianchiML , VaiS , MorandiL , BaranelloG , PasanisiB , RubinC . Effects of low‐magnitude high‐frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy. Journal of Bone and Mineral Research2013;28(Suppl 1):Poster No: LB‐SU03. [EMBASE: 71508066] ">Bianchi 2013</a> </p> <p><a href="./references#CD010899-bbs2-0001" title="BianchiML , VaiS , MorandiL , BaranelloG , PasanisiB , RubinC . Effects of low‐magnitude high‐frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy. Journal of Bone and Mineral Research2013;28(Suppl 1):Poster No: LB‐SU03. [EMBASE: 71508066] ">Bianchi 2013</a> examined the benefits of low‐magnitude high‐frequency vibration by randomising 21 ambulant children with DMD taking corticosteroids (mean age 9.3 ± 3.9 years) to either vibration devices (N = 11) or placebo devices (N = 10). Spine, hip, and whole‐body bone mineral density measurements were taken at baseline, six, and 12 months to monitor change in each treatment group. Bone mineral density significantly increased at 12 months versus baseline in the active group only (spine bone mineral apparent density (BMAD): +7.9%, P &lt; 0.02; total body (TB): +6.8%, P &lt; 0.02; femoral neck: +9.8%, P &lt; 0.01). There was "no change or a decrease" in bone mineral density versus baseline in the placebo group (spine BMAD: ‐2.9%; TB: ‐3.9%; femoral neck: ‐4.8%). All children tolerated whole‐body vibration treatment. The abstract provided no information on fractures. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010899-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010899-sec-0067"></div> <section id="CD010899-sec-0068"> <h3 class="title" id="CD010899-sec-0068">Summary of main results</h3> <p>This review was only able to include two randomised studies involving a total of 34 boys with Duchenne muscular dystrophy (DMD) (<a href="./references#CD010899-bbs2-0001" title="BianchiML , VaiS , MorandiL , BaranelloG , PasanisiB , RubinC . Effects of low‐magnitude high‐frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy. Journal of Bone and Mineral Research2013;28(Suppl 1):Poster No: LB‐SU03. [EMBASE: 71508066] ">Bianchi 2013</a>; <a href="./references#CD010899-bbs2-0002" title="EudraCT2009‐017649‐67 . Bone health in Duchenne muscular dystrophy ‐ a case controlled study of risedronate use. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐017649‐67 (accessed 18 December 2015). McSweeneyN , McKennaM , Van DerKampS , KilbaneM , McDonnellC , MurphyN , et al. Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial. Hormone Research in Paediatrics2014;82(Suppl 1):196‐7. [EMBASE: 71653083] ">McSweeney 2014</a>). One study compared risedronate plus calcium and vitamin D with calcium and vitamin D alone; the other compared the effects of whole‐body vibration with a placebo intervention. Neither study was published except in abstract form. Although each trial reported improvements in bone mineral density with active treatment over baseline, the abstracts provide insufficient data for analysis or to assess the quality of the evidence. </p> <section id="CD010899-sec-0069"> <h4 class="title">Evidence from non‐randomised studies</h4> <p>In the absence of data from studies meeting the inclusion criteria for this review, we detailed results of non‐randomised studies to inform future trial design and provide a platform for new RCTs of needed interventions to improve or stabilise bone health in DMD. </p> <section id="CD010899-sec-0070"> <h5 class="title">Bisphosphonates</h5> <p>No RCTs of alendronate in boys with DMD have been conducted.</p> <p>A small retrospective study assessed the effects of alendronate in 29 participants with DMD with a mean age of 12 years (23/29 participants had been treated with corticosteroids) (<a href="./references#CD010899-bbs2-0010" title="HoustonC , MathewsK , Shibli‐RahhalA . Bone density and alendronate effects in Duchenne muscular dystrophy patients. Muscle &amp; Nerve2014;49(4):506‐11. [PUBMED: 23835890] ">Houston 2014</a>). Nineteen boys had dual‐energy X‐ray absorptiometry (DXA) measurements taken during alendronate treatment over a mean of 3.7 years. This study reported a non‐significant effect in favour of alendronate on lumbar spine bone mineral density Z‐score (<a href="./references#CD010899-bbs2-0010" title="HoustonC , MathewsK , Shibli‐RahhalA . Bone density and alendronate effects in Duchenne muscular dystrophy patients. Muscle &amp; Nerve2014;49(4):506‐11. [PUBMED: 23835890] ">Houston 2014</a>). The lumbar spine bone mineral density Z‐score increased from ‐2.09 to ‐1.65 (P = 0.38). In comparison, seven participants not taking alendronate but taking corticosteroids only also showed an increase in the mean lumbar spine Z‐score (from ‐1.71 to ‐1.44 (P = 0.30). This increase could have been caused artificially by scoliosis. In another study, 16 boys taking alendronate over two years maintained a mean lumbar spine Z‐score of less than ‐1 (<a href="./references#CD010899-bbs2-0009" title="HawkerGA , RidoutR , HarrisVA , ChaseCC , FieldingLJ , BiggarWD . Alendronate in the treatment of low bone mass in steroid‐treated boys with Duchennes muscular dystrophy. Archives of Physical Medicine and Rehabilitation2005;86(2):284‐8. [PUBMED: 15706555] ">Hawker 2005</a>). Each boy was taking deflazacort and bone protection (calcium and vitamin D supplements). Improvements in spinal Z‐scores were significantly associated with starting bisphosphonates at a younger age (P = 0.01). In both of the above studies a mild gastrointestinal side‐effect was the major complaint associated with alendronate. </p> <p>A retrospective study examined 52 children with DMD taking oral risedronate treatment (treated) for a mean duration of 3.6 years while taking long‐term corticosteroids (<a href="./references#CD010899-bbs2-0015" title="SrinivasanR , RawlingsD , WoodCL , CheethamT , MorenoAC , MayhewA , et al. Prophylactic oral bisphosphonate therapy in Duchenne muscular dystrophy. Muscle &amp; Nerve2016;54(1):79‐85. [DOI: 10.1002/mus.24991; PUBMED: 26599341] ">Srinivasan 2016</a>). The investigators also collected data from a historical comparison group of children with DMD who took corticosteroids alone (N = 15). Risedronate‐treated children also received vitamin D supplementation of 800 IU/day to 1000 IU/day; it is not clear if the untreated children also received vitamin D. Risedronate was stopped in 9/52 children due to side‐effects (abdominal pain, vomiting, constipation, joint pain, flu‐like symptoms, and dizziness). DXA results were available in 35 children who continued risedronate treatment for over 12 months. The treated group DXA scores remained stable (mean 0.04 (standard deviation (SD) 1.3) at baseline and ‐0.04 (1.2) at final assessment, mean follow‐up: 4.9 years). The untreated group mean (SD)‐adjusted Z‐score decreased from ‐0.1 (1.3) to ‐1.00 (1.3) (mean follow‐up: 6.2 years). During this study, three 'treated' children, all with baseline Z‐scores of less than ‐1 developed lumbar vertebral fractures. This study did not assess the presence of asymptomatic vertebral fractures. Given that it was not clear if the untreated group received vitamin D, it is unclear whether or not the improvement in bone mineral density was due to risedronate or vitamin D or a combination of both. Although no child experienced osteonecrosis of the jaw, a significant proportion of participants stopped taking risedronate because of side‐effects. </p> <p><a href="./references#CD010899-bbs2-0012" title="SbrocchiAM , RauchF , JacobP , McCormickA , McMillanHJ , MatzingerMA , et al. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporosis International2012;23(11):2703‐11. [PUBMED: 22297733] ">Sbrocchi 2012</a> retrospectively studied intravenous bisphosphonate (pamidronate or zoledronic acid) treatment for painful vertebral fractures in boys with DMD. At baseline, there were 27 vertebral fractures among the seven boys. After two years of bisphosphonate treatment, 17 of the fractures showed an improved vertebral height ratio, 10 vertebrae were stabilised, and no vertebrae showed a reduced vertebral height ratio. Treatment did not prevent the development of new vertebral fractures in some participants, but it did remove the associated back pain completely in three boys and improved back pain in the remaining four. The median change in lumbar spine bone mineral density Z‐score was 0.5 SD (interquartile range: ‐0.3 to 1.7). Side‐effects occurred mostly with the first dose of intravenous bisphosphonate treatment. </p> <p>From the non‐randomised studies available, bisphosphonate treatment may stabilise bone mineral density. It is not clear if bisphosphonates prevent fragility fractures from the data available. The effect of bisphosphonates may well depend upon the time they are started in relation to bone fragility appearing. </p> </section> <section id="CD010899-sec-0071"> <h5 class="title">Vitamin D and calcium</h5> <p>A prospective study in DMD involving 33 participants taking corticosteroids for three years reported that 67% (22 of 33) had an increase in bone mineral density in response to vitamin D (calcifediol and 25‐dihydroxyvitamin Dɜ (25OHD)) and increased dietary calcium (<a href="./references#CD010899-bbs2-0004" title="BianchiML , MorandiL , AndreucciE , VaiS , FrasunkiewiczJ , CottafavaR . Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteoporosis International2011;22(2):529‐39. [PUBMED: 20458570] ">Bianchi 2011</a>). During the first year of the study, participants had increased dietary calcium but no additional vitamin D, and the bone mineral density decreased at the lumbar spine in all participants, with measured urinary calcium and serum 25OHD levels below normal. In 20 participants, serum 25OHD levels were below 20 ng/ml. During the following years, participants took calcifediol (0.8 mcg/kg/day) and increased dietary calcium (11,236 mg/day, P &lt; 0.001). The bone mineral density at the spine significantly increased in 22 participants, urinary calcium increased to normal levels, and serum calcium and 25OHD returned to normal levels. No vertebral fractures occurred during the three‐year study, but seven fractures of the leg and foot occurred: four in the non‐treatment year and three in the following treatment years. The overall increase in both lumbar spine and total body bone mineral density were not thought to be associated with an increase in body (bone) size and pubertal development, as most participants were prepubertal. </p> </section> <section id="CD010899-sec-0072"> <h5 class="title">Weight‐bearing exercise</h5> <p>Six participants with DMD (median age: 6.8 years) walking without assistance and taking corticosteroids had whole‐body vibration therapy two or three times a week for 10 weeks and were assessed for one year (<a href="./references#CD010899-bbs2-0014" title="SöderpalmAC , KroksmarkAK , MagnussonP , KarlssonJ , TuliniusM , Swolin‐EideD . Whole body vibration therapy in patients with Duchenne muscular dystrophy ‐ a prospective observational study. Journal of Musculoskeletal &amp; Neuronal Interactions2013;13(1):13‐8. [PUBMED: 23445910] ">Söderpalm 2013</a>). No significant changes occurred in bone mineral density in total body, spine, hip, or heel bone or bone markers after the intervention treatment period. No fractures occurred before or during the study. This was a very small observational study with no controls; hence, we could draw no clinical conclusions. </p> </section> </section> </section> <section id="CD010899-sec-0073"> <h3 class="title" id="CD010899-sec-0073">Overall completeness and applicability of evidence</h3> <p>Limited reports from two small studies are only available in published conference proceedings at this time. There is as yet no fully published evidence from randomised trials. </p> <section id="CD010899-sec-0074"> <h4 class="title">Vitamin D, calcium, and testosterone</h4> <p>We identified no randomised or controlled trials to assess vitamin D, calcium, and testosterone treatment for corticosteroid‐induced osteoporosis and fragility fractures in DMD. </p> </section> </section> <section id="CD010899-sec-0075"> <h3 class="title" id="CD010899-sec-0075">Quality of the evidence</h3> <p>We cannot fully assess the quality of the studies from the abstract publications. The two included studies met prespecified eligibility criteria and had small sample sizes (N = 13 and N = 21). Both trials reported that they randomised participants to an intervention group or no intervention or placebo group. The low‐magnitude, high‐frequency vibration study reported blinding (<a href="./references#CD010899-bbs2-0001" title="BianchiML , VaiS , MorandiL , BaranelloG , PasanisiB , RubinC . Effects of low‐magnitude high‐frequency vibration on bone density, bone resorption and muscular strength in ambulant children affected by Duchenne muscular dystrophy. Journal of Bone and Mineral Research2013;28(Suppl 1):Poster No: LB‐SU03. [EMBASE: 71508066] ">Bianchi 2013</a>), but this was unclear in the bisphosphonate study (<a href="./references#CD010899-bbs2-0002" title="EudraCT2009‐017649‐67 . Bone health in Duchenne muscular dystrophy ‐ a case controlled study of risedronate use. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐017649‐67 (accessed 18 December 2015). McSweeneyN , McKennaM , Van DerKampS , KilbaneM , McDonnellC , MurphyN , et al. Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial. Hormone Research in Paediatrics2014;82(Suppl 1):196‐7. [EMBASE: 71653083] ">McSweeney 2014</a>). From the <a href="./references#CD010899-bbs2-0002" title="EudraCT2009‐017649‐67 . Bone health in Duchenne muscular dystrophy ‐ a case controlled study of risedronate use. www.clinicaltrialsregister.eu/ctr‐search/search?query=eudract_number:2009‐017649‐67 (accessed 18 December 2015). McSweeneyN , McKennaM , Van DerKampS , KilbaneM , McDonnellC , MurphyN , et al. Risedronate use in Duchenne muscular dystrophy: a pilot randomised control trial. Hormone Research in Paediatrics2014;82(Suppl 1):196‐7. [EMBASE: 71653083] ">McSweeney 2014</a> abstract, it was unclear if participants in the intervention group were taking corticosteroids or not. </p> <p>Of the excluded studies, four were retrospective cohort studies or uncontrolled studies with a small sample size (<a href="./references#CD010899-bbs2-0005" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. [PUBMED: 15336688] ">Biggar 2004</a>; <a href="./references#CD010899-bbs2-0006" title="CohranVC , GriffithsM , HeubiJE . Bone mineral density in children exposed to chronic glucocorticoid therapy. Clinical Pediatrics2008;47(5):469‐75. [PUBMED: 18378941] ">Cohran 2008</a>; <a href="./references#CD010899-bbs2-0009" title="HawkerGA , RidoutR , HarrisVA , ChaseCC , FieldingLJ , BiggarWD . Alendronate in the treatment of low bone mass in steroid‐treated boys with Duchennes muscular dystrophy. Archives of Physical Medicine and Rehabilitation2005;86(2):284‐8. [PUBMED: 15706555] ">Hawker 2005</a>; <a href="./references#CD010899-bbs2-0015" title="SrinivasanR , RawlingsD , WoodCL , CheethamT , MorenoAC , MayhewA , et al. Prophylactic oral bisphosphonate therapy in Duchenne muscular dystrophy. Muscle &amp; Nerve2016;54(1):79‐85. [DOI: 10.1002/mus.24991; PUBMED: 26599341] ">Srinivasan 2016</a>). These studies had many limitations and provided very low quality evidence. </p> </section> <section id="CD010899-sec-0076"> <h3 class="title" id="CD010899-sec-0076">Potential biases in the review process</h3> <p>There were few limitations to this process. The small randomised controlled trials performed in DMD are unlikely to capture and provide high‐quality adverse event data, especially for rare events. The comprehensive searches were updated throughout the review process when necessary. </p> </section> <section id="CD010899-sec-0077"> <h3 class="title" id="CD010899-sec-0077">Agreements and disagreements with other studies or reviews</h3> <p>We examined published systematic reviews that analysed interventions to prevent corticosteroid‐induced osteoporosis and fragility fractures in other conditions. </p> <section id="CD010899-sec-0078"> <h4 class="title">Bisphosphonates</h4> <p>Reviews of treatments for corticosteroid‐induced osteoporosis in cystic fibrosis, neuromuscular disease, and chronic illnesses found extensive variation in the choice of bisphosphonate, dosing regimen, and outcome measurement (<a href="./references#CD010899-bbs2-0065" title="ConwellLS , ChangAB . Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD002010.pub4] ">Conwell 2014</a>; <a href="./references#CD010899-bbs2-0235" title="WardL , TriccoAC , PhuongP , CranneyA , BarrowmanN , GabouryI , et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005324.pub2] ">Ward 2007b</a>). Bisphosphonates had a positive effect on the lumbar spine bone mineral density, especially in the short term, although there was some heterogeneity. </p> <p>The trials reviewed, <a href="./references#CD010899-bbs2-0065" title="ConwellLS , ChangAB . Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD002010.pub4] ">Conwell 2014</a> and <a href="./references#CD010899-bbs2-0236" title="WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. The Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. [PUBMED: 21106710] ">Ward 2011</a>, reported no new fractures in treatment groups over a two‐year period. </p> <p>In <a href="./references#CD010899-bbs2-0235" title="WardL , TriccoAC , PhuongP , CranneyA , BarrowmanN , GabouryI , et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005324.pub2] ">Ward 2007b</a>, although bisphosphonates were well tolerated, the major complaint was bone pain in those taking bisphosphonates but not taking corticosteroids (odds ratio (OR) 18.52, 95% confidence interval (CI) 5.39 to 63.57, six trials). This effect was mostly related to intravenous bisphosphonates (OR 14.17, 95% CI 3.64 to 55.17) and oral risedronate (OR 43.59, 95% CI 2.27 to 837.56). <a href="./references#CD010899-bbs2-0065" title="ConwellLS , ChangAB . Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD002010.pub4] ">Conwell 2014</a> listed gastrointestinal effects as a major side‐effect. </p> <p>Overall, both reviews found insufficient evidence to justify the routine use of the bisphosphonates in clinical care to prevent or treat corticosteroid‐induced osteoporosis and fractures (<a href="./references#CD010899-bbs2-0065" title="ConwellLS , ChangAB . Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 3. [DOI: 10.1002/14651858.CD002010.pub4] ">Conwell 2014</a>; <a href="./references#CD010899-bbs2-0235" title="WardL , TriccoAC , PhuongP , CranneyA , BarrowmanN , GabouryI , et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005324.pub2] ">Ward 2007b</a>). The included trials were too short to monitor vertebral fracture events and treatment adequately. </p> </section> <section id="CD010899-sec-0079"> <h4 class="title">Vitamin D</h4> <p>Participants with cystic fibrosis taking vitamin D supplements had significantly higher serum levels (mean difference (MD) 7.24 ng/ml, 95% confidence interval 5.01 to 9.46 ng/ml) than those taking a placebo (<a href="./references#CD010899-bbs2-0090" title="FergusonJH , ChangAB . Vitamin D supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD007298.pub4; PUBMED: 24823922] ">Ferguson 2014</a>). Vitamin D supplementation was found not to improve bone density in healthy children with normal vitamin D levels, but was found to be clinically useful in children with low serum vitamin D levels by preventing bone loss at the lumbar spine (<a href="./references#CD010899-bbs2-0116" title="HomikJ , Suarez‐AlmazorME , SheaB , CranneyA , WellsG , TugwellP . Calcium and vitamin D for corticosteroid‐induced osteoporosis. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000952] ">Homik 1998</a>; <a href="./references#CD010899-bbs2-0242" title="WinzenbergTM , PowellS , ShawKA , JonesG . Vitamin D supplementation for improving bone mineral density in children. Cochrane Database of Systematic Reviews2010, Issue 10. [DOI: 10.1002/14651858.CD006944.pub2] ">Winzenberg 2010</a>). </p> <p>The vitamin <b>D</b> Individual <b>P</b> atient <b>A</b> nalysis of <b>R</b> andomized <b>T</b>rials showed that vitamin D given alone was not effective in preventing fractures (risk ratio (RR) 0.92, 95% CI 0.86 to 0.99, P = 0.025), but if taken with calcium, the combination reduced the risk of vertebral fragility fractures (<a href="./references#CD010899-bbs2-0074" title="DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ2010;340:b5463. [PUBMED: 20068257] ">DIPART 2010</a>). Evidence from randomised and cross‐over design trials and meta‐analysis supports the use of calcium in combination with vitamin D as a preventive treatment for bone loss in the spine of people treated with corticosteroids and adults over 50 years of age (<a href="./references#CD010899-bbs2-0026" title="AminS , LaValleyMP , SimmsRW , FelsonDT . The role of vitamin D in corticosteroid‐induced osteoporosis: a meta‐analytic approach. Arthritis &amp; Rheumatism1999;42(8):1740‐51. [PUBMED: 10446876] ">Amin 1999</a>; <a href="./references#CD010899-bbs2-0116" title="HomikJ , Suarez‐AlmazorME , SheaB , CranneyA , WellsG , TugwellP . Calcium and vitamin D for corticosteroid‐induced osteoporosis. Cochrane Database of Systematic Reviews1998, Issue 2. [DOI: 10.1002/14651858.CD000952] ">Homik 1998</a>; <a href="./references#CD010899-bbs2-0189" title="RianthavornP , PisutikulK , DeekajorndechT , TepmongkolS , SuphapeetipornK . Prevention of bone loss in children receiving long‐term glucocorticoids with calcium and alfacalcidol or menatetrenone. Journal of Pediatric Endocrinology and Metabolism2012;25(3‐4):307‐12. [PUBMED: 22768661] ">Rianthavorn 2012</a>; <a href="./references#CD010899-bbs2-0220" title="TangBM , EslickGD , NowsonC , SmithC , BensoussanA . Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta‐analysis. Lancet2007;370(9588):657‐66. [PUBMED: 17720017] ">Tang 2007</a>; <a href="./references#CD010899-bbs2-0232" title="WaradyBD , LindsleyCB , RobinsonFG , LukertBP . Effects of nutritional supplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy. The Journal of Rheumatology1994;21(3):530‐5. [PUBMED: 8006898] ">Warady 1994</a>). Further research is required to investigate the effect of vitamin D levels on bone strength of patients with DMD (<a href="./references#CD010899-bbs2-0243" title="WongB , HuSY , KingA , HornP . P4.12 Vitamin D and bone health in Duchenne muscular dystrophy (DMD) patients. Abstracts/Neuromuscular Disorders2010;20(9):662. ">Wong 2010</a>). </p> </section> <section id="CD010899-sec-0080"> <h4 class="title">Weight‐bearing exercise</h4> <p>No useful data were available from studies of weight‐bearing exercise in people over 40 with vertebral fragility fractures (<a href="./references#CD010899-bbs2-0171" title="PapaioannouA , AdachiJD , WinegardK , FerkoN , ParkinsonW , CookRJ , et al. Efficacy of home‐based exercise for improving quality of life among elderly women with symptomatic osteoporosis‐related vertebral fractures. Osteoporosis International2003;14(8):677‐82. [PUBMED: 12879220] ">Papaioannou 2003</a>). A systematic review of vibration treatment for osteoporosis is published only as a protocol (<a href="./references#CD010899-bbs2-0149" title="LorenzenC , NaughtonGA , CameronM , WilliamsMD , GreeneD . Whole body vibration for preventing and treating osteoporosis. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD008417] ">Lorenzen 2010</a>). </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010899-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/urn:x-wiley:14651858:media:CD010899:CD010899-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/image_t/tCD010899-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="A flow diagram illustrating the study selection process." data-id="CD010899-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/image_n/nCD010899-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>A flow diagram illustrating the study selection process.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/image_n/nCD010899-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010899-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/urn:x-wiley:14651858:media:CD010899:CD010899-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/image_t/tCD010899-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Green = low risk of bias; yellow = unclear risk of bias; red (not shown) = high risk of bias." data-id="CD010899-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/image_n/nCD010899-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. Green = low risk of bias; yellow = unclear risk of bias; red (not shown) = high risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/media/CDSR/CD010899/image_n/nCD010899-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010899-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Spine and whole‐body Z‐scores (McSweeney 2014)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Risedronate (plus calcium and vitamin D supplementation)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Control (calcium and vitamin D supplementation alone)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12‐month</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median spine Z‐score (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.75 (‐1.2 to ‐3.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.8 (‐1.7 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.2 (‐4.1 to ‐1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.6 (‐8.4 to ‐0.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median whole‐body Z‐score (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.95 (‐0.5 to 2.7)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (‐1.0 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.2 (‐1.6 to 4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.8 (‐3.1 to 3)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>A median of ‐1.95 is outside the range given, but we were unable to confirm correct figures with the study author. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Spine and whole‐body Z‐scores (McSweeney 2014)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010899.pub2/full#CD010899-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010899.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010899-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010899-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010899-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD010899-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010899-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010899\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010899\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010899\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010899\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010899\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010899.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010899.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010899.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010899.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010899.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719950177"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010899.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719950181"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010899.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df538caf39368',t:'MTc0MDcxOTk1MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 